2013

Biological effects of trogocytosis on CD4+ T lymphocytes

Douglas Grant Osborne

The University of Montana

Let us know how access to this document benefits you.

Follow this and additional works at: https://scholarworks.umt.edu/etd

Recommended Citation

Osborne, Douglas Grant, "Biological effects of trogocytosis on CD4+ T lymphocytes" (2013). Graduate Student Theses, Dissertations, & Professional Papers. 100.
https://scholarworks.umt.edu/etd/100

This Dissertation is brought to you for free and open access by the Graduate School at ScholarWorks at University of Montana. It has been accepted for inclusion in Graduate Student Theses, Dissertations, & Professional Papers by an authorized administrator of ScholarWorks at University of Montana. For more information, please contact scholarworks@mso.umt.edu.
BIOLOGICAL EFFECTS OF TROGOCYTOSIS ON CD4+ T LYMPHOCYTES

By

DOUGLAS GRANT OSBORNE

BS, University of Washington, Seattle, Washington, 2005

Dissertation/Thesis

presented in partial fulfillment of the requirements
for the degree of

Doctor of Philosophy
Microbiology, Integrated Microbiology and Biochemistry

The University of Montana
Missoula, MT

January 2013

Approved by:

Sandy Ross, Associate Dean of The Graduate School
Graduate School

Dr. Bill Granath, Chair
Integrated Microbiology and Biochemistry

Dr. Scott Wetzel, Thesis advisor
Integrated Microbiology and Biochemistry

Dr. Jesse Hay
Integrated Microbiology and Biochemistry

Dr. Kevin Roberts
Center for Environmental Health and Safety

Dr. Dave Shepherd
Center for Environmental Health and Safety

Dr. Mike Minnick
Integrated Microbiology and Biochemistry
Abstract

Antigen recognition by CD4$^+$ T cells leads to large-scale spatial and temporal molecular redistributions, forming the immunological synapse. We have previously shown that upon dissociation, T cells capture large membrane fragments from antigen-presenting cells directly from the immunological synapse. The mechanism and biological significance of this process, termed trogocytosis, is still unclear. In this thesis I examined the impact that trogocytosis has on the individual T cell after capturing molecules from the antigen presenting cell. I employed murine fibroblast cell lines expressing an I-E$^k$ molecule loaded with a covalently attached antigenic peptide (moth cytochrome C 88-103) and with or without a GFP-tagged cytoplasmic tail as antigen presenting cells for T cells from a peptide-specific TCR transgenic mouse. Using a combination of high-resolution microscopy and flow cytometry, I showed that the trogocytosed material is retained on the surface of the T cell and is associated with sustained signaling after removal of the antigen presenting cells. The intracellular trogocytosis correlates with alterations in and is associated with sustained survival of the trogocytosis-positive (trog$^+$) cells in vitro. I also showed that sustained signaling in trog$^+$ T cells occurs at the trogocytosed spot and is initiated by the trogocytosed material. I conclude, that after trogocytosis, trog$^+$ T cells present antigen and induce activation of antigen-specific naïve T cells. The findings from this thesis will help to elucidate the role of trogocytosis on CD4$^+$ T cells.
# Table of Contents

Abstract iii  
Table of contents iv  
Acknowledgements x

## Chapter 1: Introduction 1

T Cell Activation 1  
  TCR signaling 4  
  Costimulation and cytokines 8  
Immunological Synapse 9  
  Immunological synapse morphology 10  
  Immunological synapse function 13  
Trogocytosis 16  
  Molecules trogocytosed and requirements for T cell trogocytosis 18  
  Trogocytosis mechanism 22  
  Integration of trogocytosed molecules into the T cell plasma membrane 23  
  The function of trogocytosis 26  
    Trog⁺ T cells as APCs 26  
    Trogocytosis intrinsic function 27  
Rationale 30

## Chapter 2: Materials and Methods 33

Animals 33  
Antibodies and Staining Reagents 33  
Antigen presenting cells 34  
In vitro T cell priming 35  
Standard in vitro trogocytosis assay 36  
In vitro naïve T cell trogocytosis assay 37
Flow cytometry 38
Examination of trogocytosis associated intracellular signaling 39
   by flow cytometry 40
Immune synapse microscopy 41
Microscopic analysis of trogocytosis 42
Image analysis 43
TCR signaling inhibition 44
T-T presentation 45
Peptide affinity 46
qRT-PCR 47
Statistical analysis and graphing 48

Chapter 3: Results 49

Measuring Trogocytosis 49
Naïve T cell Trogocytosis 51
Trogocytosis correlates with naïve T cell proliferation 54
Trogocytosis negative cells recognize antigen and are activated similar 56
   to trogocytosis positive cells 58
Sustained CD69 expression in trog^+ T cells 59
Selective survival of trogocytosis^+ CD4^+ T cells in vitro after removal of 62
   APC 63
Sustained TCR-proximal intracellular signaling in trogocytosis^+ T cells 64
Trogocytosed MHC:peptide molecules co-localize with TCR-proximal 65
   signaling molecules in trog^+ T cells 67
Sustained TCR-proximal signaling in trog^+ T cells 68
Sustained TCR-distal signaling in trog^+ T cells 70
Trogocytosed molecules induce sustained signaling in trog^+ T cells 71
T-T Ag presentation 72

Chapter 4: Discussion 73

Kinetics, activation, proliferation, and selective survival of trog^+ T cells 74
Sustained signaling by the trogocytosed material 78
Trogocytosis signaling and spots 98
T-T Ag presentation 98

**Chapter 5: Future Directions** 100

Peptide affinity 100
Gene expression of trog$^+$ T cells 102
T cell subsets and trogocytosis 103
T-T Ag presentation 104

References 106
Figures:

Fig. 1 – Proximal signaling complex. 6

Fig. 2 – Overview of TCR signaling pathways. 7

Fig. 3 – Immune synapse: supramolecular activation complex organization and content. 11

Fig. 4 – Immune synapse formation. 13

Fig. 5 – TCR signaling at the c-SMAC. 15

Fig. 6 – CD4⁺ T cell trogocytosis via the immunological synapse. 18

Fig. 7 – Measuring trogocytosis using flow cytometry. 20

Fig. 8 – Proposed mechanism for trogocytosis. 24

Fig. 9 – Trogocytosed molecules are integrated into the T cell membrane. 25

Fig. 10 – Measuring trogocytosis using different APC-labeling methods. 49

Fig. 11 – Primary vs. secondary stimulation of naïve T cell shows increased trogocytosis during the secondary stimulation with APCs. 52

Fig. 12 – In vitro trogocytosis is associated with more rapid proliferation of naïve T cells. 55

Fig. 13 – Trog⁺ and trog⁻ T cells have an activated phenotype. 57

Fig. 14 – Sustained CD69 expression in trog⁺ CD4⁺ T cells. 59

Fig. 15 – Selective survival of trog⁺ T cells. 61

Fig. 16 – Testing phosflow. 63

Fig. 17 – TCR-proximal signaling is sustained in trogocytosis⁺ CD4⁺ T cells using phosflow. 65

Fig. 18 – TCR signaling-associated molecules are associated with trogocytosed molecules on the T cell surface in conjugate with APC. 68

Fig. 19 – Measuring the thickness of TCR signaling-associated molecules 69
across the distal T cell surface and T-APC interface.

Fig. 20 - Measuring pLck staining intensity across the distal T cell surface and the T-APC interface.

Fig. 21 - Proximal TCR signaling-associated molecules are associated with trogocytosed molecules on the recovered T cell surface.

Fig. 22 - Distal TCR signaling-associated molecules are associated with trogocytosed molecules on the recovered T cell surface.

Fig. 23 - Correlation between the size of trogocytosed MHC:peptide and TCR/pERK staining.

Fig. 24 - TCR-proximal signaling is sustained by trogocytosed molecules in trog\(^+\) cells.

Fig. 25 - pZAP-70 rebounds and localizes with trogocytosed GFP-MHC in trog\(^+\) T cells following the removal of PP2.

Fig. 26 - TCR-distal signaling is sustained by trogocytosed molecules in trog\(^+\) CD4\(^+\) T cells using phosflow.

Fig. 27 - TCR-distal signaling is sustained by trogocytosed molecules in trog\(^+\) CD4\(^+\) T cells.

Fig. 28 - pERK1/2 rebounds and localized with trogocytosed GFP-MHC in trog\(^+\) T cells following the removal of PP2.

Fig. 29 – T-T presentation.

Fig. 30 – Autopresentation: proposed autopresentation hypothesis for how trogocytosis leads to sustained intracellular signaling.

Fig. 31 – Peptide affinity and trogocytosis.

Fig. 32 – qRT-PCR of trog\(^+\) T cells.
Tables:

Table 1 - qRT-PCR primer sets 45
Acknowledgements:

Scott A. Wetzel – For giving me the opportunity to pursue openly my research and introducing me the greatest immune cell: T lymphocytes. I owe a large part of my laboratory skills to him.

Lindsay Thuesen – For helping me maintain mice and cell lines, and being a great friend.

Thesis Committee Members (Kevin Roberts, Bill Granath, Mike Minnick, Dave Shepherd, and Jesse Hay) for mentoring me and their encouragement through my graduate work.

Pam Shaw – For training and assisting me with flow cytometry, and specifically helping me with clogs and compensation.

Current and Former Members of the Wetzel lab: for taking care of my responsibilities when I was MIA, for trusting me to assist them in their research, and maintaining an open environment to discuss ideas and troubles.

My wife Jessa: For her incredible patience through the process and her kind nature.
Chapter 1: 

Introduction 

T cell activation 

During an adaptive immune response, T lymphocytes play a central role in the recognition and clearance of pathogens. The two general types of αβ T cells are CD8+ and CD4+, named for the coreceptor that the cells express. CD8+ T cells, or cytotoxic T lymphocytes (CTL), are essential in cellular immune responses. CD8+ T cells lyse target cells by releasing cytolytic granules containing perforin, a protein that forms pores in the cell membrane, and granzymes; proteases that induce apoptosis. The second type of T cell, the CD4+ T cells, or helper T cells, will be the main focus of this thesis. Upon activation, naïve CD4+ T cells can differentiate into various helper T cell (T\text{H}) effector subsets, among these are the T\text{H}1, T\text{H}2, T\text{H}17, T\text{FH}, and T\text{reg} subsets. T\text{H}1 cells play a role in cellular immune responses, by expressing IL-2 and proinflammatory cytokines such as IFN\text{γ} along with helping in the activation of CD8+ T cells, all leading to the clearance of intracellular pathogens (1-3). T\text{H}2 cells play a role in humoral immune responses, by expressing cytokines such as IL-4, IL-5, IL-10, and IL-13, which help boost Ig production and lead to the production of immunoglobulin E antibodies, which are responsible for the clearance of extracellular parasites (1-3). T\text{H}17 cells are involved in the production of IL-17 and in autoimmunity (4). T\text{FH} cells (follicular B helper T cells) regulate the development of antigen-specific B cell immunity (5). T\text{reg} cells (regulatory T cells) are involved in the suppression of an immune response (6). To become activated
and to differentiate into the effector CD4$^+$ T cell subsets, T cells require presentation of antigen (Ag) by a professional antigen-presenting cell (APC).

Ag presentation involves the expression of polymorphic MHC molecules loaded with specific antigenic peptide fragments on the APC membrane. The recognition of the specific MHC:peptide complex by the TCR induces a series of signaling cascades in the T cell leading to activation, differentiation, generation of effector function, and proliferation. TCR:pMHC engagement (called signal 1) is but 1 of 3 signals that are required for full CD4$^+$ T cell activation and differentiation. The second signal, costimulation, is induced by APCs recognizing Pathogen Associated Molecular Patterns (PAMPs). This “danger” signal (7, 8) leads to increases in the expression of costimulatory molecules, such as CD80 and CD86, which engage costimulatory receptors, such as CD28, on the surface of the T cell (8-10). The costimulatory signal augments TCR signaling (9), helping to increase activation, cytokine production, and proliferation. The final signal for full T cell activation and differentiation (signal 3) comes from the binding of cytokines to their receptors on the CD4$^+$ T cell. This induces signaling that drives proliferation and differentiation of naïve cells into one of the effector subsets.

The interacting molecules at the T-APC interface (including TCR:pMHC, costimulatory molecules, and adhesion molecules) along with intracellular signaling molecules and the T cell cytoskeleton, are spatially and temporally segregated in a structure termed the immunological synapse. The signaling through the synapse can lead to alterations in T cell function, activation of naïve and effector T cells (11), thymic selection (12), and/or cell death (13), and inactivation, also known as anergy (14).
When naïve T cells in the lymph nodes first encounter Ag, there is increased expression of CD69 (5) and downmodulation of the TCR (15-17). Increased CD69 expression, originally termed the “very early activation marker”, is a sign of early activation and has been found to help in T cell proliferation, signal transduction, and is responsible for retention in the lymph nodes during T cell activation (18, 19). TCR downmodulation occurs during activation (16, 17) via proposed phagocytic mechanisms (20-22). TCR downmodulation is hypothesized to allow for serial TCR triggering (23, 24), where continuous TCR interactions with the pMHC can occur and desensitization of the activated T cell (16, 25). Increases in CD69 and downmodulation of the TCR precedes increased expression of CD25 (26), and the loss of CD62L (11) expression. The increase in CD25 (IL-2 receptor α) expression allows the cell to bind IL-2 with significantly higher affinity, which helps to increase T cell proliferation (26-28). The decrease in the adhesion marker CD62L, also known as L-selectin, prevents the cell from recirculating through 2° lymphoid organs, like the lymph nodes, after Ag recognition and activation (29, 30). T cell activation also leads to increased expression of CD4 and CD44 (31). CD4 binds to non-polymorphic regions of the MHC and brings the Src family kinase p56Lck (Lck) into close proximity to tyrosine containing substrates (16). CD4 can also help stabilize the interactions of the TCR with the MHC (32). CD44 is an adhesion marker commonly found on activated effector/memory cells that helps in lymph node retention by binding hyaluronan on the surface of the surrounding extracellular matrix (31, 33).
**TCR signaling**

The primary signal for T cell activation occurs through the engagement of the αβ TCR heterodimer by a specific MHC:peptide molecule present on the surface of an APC. TCR engagement initiates multiple signaling pathways that lead to the activation of three primary transcription factors: nuclear factor of activated T cells (NFAT) (30, 45, 46), activator protein 1 (AP-1) (45, 46), and nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) (48). Their activation results in T cell activation, proliferation, and development of effector functions. TCR:pMHC engagement leads to both TCR conformational changes (34) and aggregation (35, 36), which contribute to the initiation of signaling by recruiting cytoplasmic and membrane-bound kinases. These phosphorylate the immunoreceptor tyrosine-based activation motifs (ITAM) on the CD3 γ, ε, δ chains, and ζ dimer associated with the αβ TCR (37).

The kinase responsible for the initial ITAM phosphorylation is p56Lck (Lck) (34, 37). A recent report suggests that the main function of CD4 is the delivery of non-covalently associated Lck to the engaged receptor, rather than the previously hypothesized stabilization of the TCR:pMHC interaction (38). Lck knockout mice display a loss of active T cells in the periphery and the thymus of mice (39). The initial phosphorylation by Lck triggers the recruitment of a Syk-family kinase, zeta associated protein 70 kDa (ZAP-70) (37). ZAP-70 contains two SH2 (Src Homology 2) domains that bind the phosphorylated ITAMs. Upon ITAM binding, ZAP-70 is itself subsequently phosphorylated by Lck and activated (37).
The activation of ZAP-70 initiates several downstream signaling pathways. Phosphorylated ZAP-70 targets two important adapter proteins for phosphorylation: the Linker of Activated T cells (LAT) and SH2 domain containing leukocyte protein of 76 kDa (SLP-76) (40, 41). The loss of either LAT or SLP-76 results in the loss of nearly all signaling downstream of the TCR (42, 43). The phosphorylation of LAT at the plasma membrane recruits SLP-76 (which is also phosphorylated by ZAP-70) and GRB2-related adapter downstream of Shc (GADS). SLP-76 forms a stable interaction with LAT through GADS, forming a multimolecular signaling complex called the proximal signaling complex (40, 41). Even though these adaptor proteins lack enzymatic activity, they are responsible for the correct orientation and assembling of the proximal signaling complex to allow for the activation of multiple signaling pathways (44-46). The adapter molecules, LAT, SLP-76, and GADS, along with adapter protein, Nck, the guanine nucleotide exchange factor (GEF) Vav1, and the IL-2-induced tyrosine kinase (Itk), join together to recruit other secondary messengers that are critical in producing T cell effector function (fig. 1; purple box, fig. 2) (45).
One of the first signaling molecules recruited to the proximal signaling complex is phospholipase Cγ1 (PLCγ1) (47). PLCγ1 is phosphorylated by Itk, which is bound to the proximal complex by the protein Vav1 (48-50). After phosphorylation, PLCγ1 helps initiate calcium release from the endoplasmic reticulum (ER) in fig. 2 red box. PLCγ1 hydrolyzes membrane phosphatidylinositol-1,4-bisphosphate (PIP2) into the soluble sugar inositol-1,4,5-triphosphate (IP3) and the lipid diacylglycerol (DAG) (51, 52). IP3 binds IP3 receptors on the ER surface, leading to the release of Ca^{2+}. Increased intracellular Ca^{2+} leads to the activation of calcium release activated calcium (CRAC) channels (53, 54) (red box, fig. 2). The Ca^{2+} binds the regulatory protein calmodulin which activates the phosphatase calcineurin and dephosphorylates and subsequently activates the cytoplasmic transcription factor NFAT (55). The dephosphorylated NFAT
enters the nucleus and along with other transcription factors, activates T cell-associated activation genes (56). The release of Ca$^{2+}$ during T cell activation can be easily monitored using imaging and flow cytometry (57, 58). PIP2 hydrolysis also produces DAG leading to the activation of the novel PKC family member protein kinase Cθ (PKCθ) (59), the guanine nucleotide binding protein Ras (through the guanine-nucleotide exchange factor (GEF) RasGRP) (60, 61), and the adaptor protein Carma1 (62). These molecules in turn activate three different downstream signaling pathways leading to the activation of the kinases ERK, JNK (63), and the transcription factor NFκB (62) (fig. 2).

Figure 2. Overview of TCR signaling pathways. Taken from Samelson et al. (64)
Carma1 phosphorylation by PKCθ leads to the phosphorylation of mitogen-associated kinase kinase kinase (MEKKK), which releases the transcription factor NFκB from inhibitor of kappa B (IκB) by phosphorylating IκB for degradation. This allows NFκB to enter the nucleus (65). The phosphorylation of MEK1/2 by the kinase Raf and MEKK by the kinase Rac leads to the phosphorylation of kinases ERK, p38, and JNK. These, in turn, help dimerize the two transcription factors Fos and Jun into the AP-1 transcription factor (66) (blue box, fig. 2). Singular activation and translocation of NFAT without AP-1 leads to a hyporesponsive state in T cells, known as anergy (67). In addition, SLP-76 and Vav1 help to activate the kinase Rac which recruits Rho family GTPase Cdc42 and the Wiskott-Aldrich syndrome protein (WASP) to the signaling complex to initiate cytoskeletal rearrangements in the cell, allowing for continued proximal signaling and longer T-APC interaction (68, 69).

Costimulation and cytokines

In addition to signal 1, TCR engagement of the MHC:peptide complex, Ag presentation that leads to T cell activation also requires a second signal that is acquired through costimulation. TCR signaling in the absence of a costimulatory signal leads to anergy (8). Cytokines, as the third signal, leads to increased activation, proliferation, differentiation, and cell homing (70).

The prototypical costimulatory interaction involves the CD28 costimulatory receptor on the surface of the T cell engaging B7 family molecules CD80 (B7-1) and CD86 (B7-2) found on the surface of APC (71). According to the danger hypothesis,
microbial products or responses to cell damage induce the APC to upregulate expression of CD80 and CD86 (8-10). As shown in fig. 2, engagement of CD28 by CD80/CD86 at the immune synapse leads to the activation of PI3K (72), which augments the TCR-mediated activation of MEKKK via the kinase Akt (73), which contributes to the subsequent activation and translocation of NFKB (74).

The combination of TCR and costimulatory signaling leads to the induction of gene expression within the T cell associated with the production of cytokines and, ultimately, effector functions. One of the main cytokines produced during T cell activation is IL-2 (75, 76). IL-2 binds the high affinity CD25-containing IL-2 receptor on the surface of the T cell activating similar pathways involved in TCR and costimulation (27), and ultimately leading to proliferation and differentiation.

**Immunological synapse**

Ag recognition by T cells, and the subsequent signaling, leads to spatial and temporal molecular rearrangement at the T-APC interface to form a structure termed the immunological synapse. These molecular rearrangements involve the clustering and spatial segregation of molecules at the T-APC interface, including TCR:pMHC, costimulatory, and adhesion molecules, along with intracellular signaling molecules and the T cell cytoskeleton. This structure was first described by Kupfer et al. in 1987 (77), who showed when murine T cells were being presented Ag by a B cell, the TCR was concentrated at the cell-cell contact area. Kupfer et al. also found that T cells reorganized microtubules and membrane-bound cytoskeleton to the cell-cell contact area (77). In a
follow up paper in 1998, Monks et al. showed that surface receptors, like the TCR, segregated into specific areas on the T cells that were in contact with the APC, called supramolecular activation complexes (SMACs) (78). The initial studies of immune synapse formation found that the formation of an immune synapse coincided with T cell activation (78, 79).

**Immunological synapse morphology**

After the initial T-APC contact and subsequent Ag recognition occurs, the adhesion molecule leukocyte function-associated antigen 1 (LFA-1) on the T cell binds to intercellular adhesion molecule 1 (ICAM-1) on the APC, leading to the formation of microclusters containing both TCR:pMHC and LFA-1/ICAM-1(80). As shown in fig.3, these TCR/MHC microclusters are translocated to the center of the T-APC contact patch in an endosomal sorting protein, TSG101, dependent mechanism (81, 82). The area where TCR microclusters translocate to has been termed the central supramolecular activation complex (c-SMAC) (78). From fig. 3, it can best be seen that the c-SMAC contains not only TCR/MHC:peptide, but also costimulatory molecule interactions CD28/B7-1, adhesion molecule CD2, and the coreceptor CD4 (78, 83). The segregation of intracellular signaling molecules PKCθ, Lck, and Fyn also occurs at the c-SMAC (78, 83). Surrounding the interactions of the TCR with MHC at the c-SMAC is a peripheral ring of integrin adhesion molecules LFA-1/ICAM-1 (78, 83). This peripheral ring has been termed the peripheral SMAC, or p-SMAC. The p-SMAC has been shown as the location for accumulation of f-actin (84) and talin, which links integrins, like LFA-1, to
actin (78, 83). Once the defined p-SMAC and c-SMAC are spatially segregated, the synapse is termed a mature immunological synapse (84).

The prototypical mature Th1 immune synapse can be characterized as a bull’s-eye with the p-SMAC surrounding the c-SMAC, and after several minutes a third ring is formed termed the distal SMAC or d-SMAC. The d-SMAC discovered by Frieberg et al., contains the phosphatase CD45 and, following 15 and 23 minutes of initial contact, both Lck and CD4 localize to the d-SMAC (85), respectively. Fig. 3 shows the organization of the immune synapse into SMACs.

![Immune synapse: supramolecular activation complex (SMAC) organization and content.](image)

The morphology of a Th1 synapse is different from the Th2 synapse (86). The differences between a Th1 and Th2 cell synapse are the localization of adhesion molecule, ICAM-1. In Th1 synapses, as shown above, a ring of ICAM-1 surrounds TCR:pMHC. In Th2 synapses, ICAM-1 did not form a ring and colocalized with TCR:pMHC (86). The difference in distribution of ICAM-1 between Th1 and Th2
synapses suggest differences in the function of the synapse between these cells. T_{H1} synapses could be used for cytotoxic functions (87), where the ring of ICAM-1 helps concentrate cytotoxic granules towards the target cell and prevent damage to bystander cells (88). T_{H2} cells are not known to have cytotoxic functions (87, 89), so there may be less need for a ring of ICAM-1.

The organization of the c-SMAC and p-SMAC in T_{H1} cells can be visualized using fluorescent microscopy, as shown in fig. 4. Using live-cell imaging and fluorescently labeled MHC:peptide and ICAM-1 attached to a planar lipid membrane, Grakoui et al. observed that when T cells interact with these molecules, large-scale molecular rearrangements occur leading to the formation of the immune synapse (79). Using time-lapse imaging, they showed that during the interaction of the T cell with molecules in the membrane, the surface molecules can be seen reordering into specific areas during a 60 minute time period, characterizing the c-SMAC and p-SMAC shown in fig. 4A (79). In fig.4B Dustin’s group shows the localization of the TCR (red and green) to the c-SMAC surrounded by ICAM-1 (blue) in the p-SMAC (90).
Figure 4. Immune synapse formation. (A) 60 minute time-lapse imaging showing the change in distribution of MHC (green) and ICAM-1 (red) receptors embedded in planar lipid bilayers when in contact with the T cell. From Grakoui et al. (79) (B) Fixed cell images showing the distribution of the T cell’s TCR ζ (green) and β (red) chains corresponding to the c-SMAC and surrounded by ICAM-1 (blue) at the p-SMAC. From Roberts. J. (90)

Immunological synapse function

The formation and organization of the immune synapse has been well studied (78, 79, 84, 85, 91, 92), but the functions of the immune synapse remain unclear. The consensus from the last decade is that LFA-1/ICAM-1 interactions slow down rapidly migrating T cells, allowing for long sustained contacts with APCs (93, 94) which may lead to immune synapse formation and T cell activation. As the synapse is formed, the SMACs stabilize the T-APC contact and lead to the segregation of signaling molecules within the contact area. This allows for concentrated and continual TCR signaling (95)
leading to T activation (11). What remains unclear is the location of TCR signaling within the immune synapse.

Over the last decade controversy has arisen over whether TCR signaling localizes to the p-SMAC or c-SMAC, in a mature synapse. Recent results suggested that TCR signaling starts in the p-SMAC and ceases in the c-SMAC (81, 96, 97). Lee et al. showed as the TCR microclusters migrate from the p-SMAC to the c-SMAC, signaling associated with these microclusters decreased (97). During synapse formation signaling can initially be seen near the c-SMAC, but after one hour the signaling is gone (97). This can be seen in the images in fig. 5A showing that peripheral phosphotyrosine (green) is lost in the c-SMAC in an immune synapse after 60 min. Following entry into the c-SMAC the microclusters are hypothesized to be degraded due to the increase of lysobisphosphatidic acid, a late endosomal marker in endosomes that are targeted for degradation (81). To sustain the signaling necessary for full T cell activation, continuous formation of signaling microclusters in the p-SMAC is required. These microclusters and the associated signaling appear to be degraded in the c-SMAC (81). This raises the possibility that the function of the c-SMAC may actually be to terminate TCR signaling. However, the role of the c-SMAC in signal termination is controversial because it has also been shown that signaling still occurs at the c-SMAC (78, 79, 98). In fig. 5B phosphotyrosine is localized to the c-SMAC after 60 min of T-APC conjugate formation (98). The images in fig. 5B are conflicting with the data shown by Lee et al. (97) in fig. 5A. These results are consistent with previous results showing signaling localized to c-SMAC (86).
Figure 5. TCR signaling at the c-SMAC. (A) No c-SMAC signaling. T cell–APC conjugates stained TCR Vβ3 (red) and phosphotyrosine (green). AND TCR transgenic splenic T cells were conjugated with antigenic peptide–loaded splenic APCs from B10.BR mice. The lower row shows DIC images of the T cell–APC conjugates. Images show peripheral signaling as the synapse forms and by 60 min signaling has returned to basal levels. From Lee et al. (97), (B) Signaling at the c-SMAC. Rested AND T cells were stimulated with peptide-loaded CH27 B cells for 1 hr. Conjugates were then fixed, permeabilized, and stained with antibodies to Vβ3 (green) and phosphotyrosine (red). Images show phosphotyrosine concentrated at the c-SMAC, conflicting with the data show in (A). From Cemerski et al. (98).

In the last decade, other roles for the immune synapse have been elucidated in CD4+ and CD8+ T cells. In CD8+ T cells, the p-SMAC is utilized as a barrier to help direct the release of cytotoxic granules towards the target cell (88, 99, 100). Stinchcombe et al. showed that CD8+ T cells form a ring of adhesion with target cells, similar to the p-SMAC formed between a CD4+ T cell and an APC (88). With the adhesion ring, lytic granules filled with perforin and granzymes were released onto the target cell (88). The immune synapse also plays a role in cytokine secretion. In 2006, Huse et al. showed IL-2 and IFN-γ accumulated at the synapse for release (101). Components of the immune synapse may play a critical role in the fate of the T cell. Recently, anergized T cells have
been shown to form an immune synapse with accumulated anergy-associated molecule, the E3 ubiquitin-protein ligase, Cbl-B (102). Anergized CD4+ T cells formed distinct p- and c-SMACs, and both SMACs showed enhanced levels of c-Cbl and Cbl-B (102).

Finally, and most relevant here, the immune synapse has been shown to be the site of intercellular membrane and membrane-associated molecule transfer from APC to T cell (88, 103-107).

**Trogocytosis**

Ag recognition by CD4+ T cells and the formation of a mature immune synapse can lead to the acquisition of APC membrane lipids and membrane-bound proteins, including cognate MHC:peptide complexes (103, 107). This phenomenon of intercellular molecule transfer has been termed trogocytosis (108). Initially, the term was used to describe the injuring of mouse embryo cells by pathogenic amoeba, wherein the amoeba would acquire membrane from the mouse cells (109, 110). In 2003, Hudrisier and colleagues applied the term trogocytosis to define the swapping of membrane and membrane-associated molecules between immune cells (108, 111).

The discovery of immune cell trogocytosis came in the 1970’s when Playfair’s group discovered the presence of B cell-derived Ig molecules on the surface of T cells (112). Although there were several important publications in the 1980’s (113-115), interest in trogocytosis and its potential immunomodulatory role was reignited in the late 1990s by the work of Mannie and colleagues (104, 116-121), Sprent *et al.* (105, 106, 122), and Hudrisier and Joly (107, 108, 111, 123-128). The general consensus of these,
and other studies, is that Ag recognition by T lymphocytes can lead to the trogocytosis of molecules from the surface of an APC. Trogocytosis requires TCR recognition of MHC:peptide ligands (103, 111, 129) and involves immune synapse formation (103) along with subsequent TCR signaling. In addition, costimulation and actin cytoskeletal rearrangements are required for efficient T cell trogocytosis (107, 108, 111, 123-128, 130).

While most studies have focused on T cells; several other immune cells have been shown to perform trogocytosis. B cells (111, 129, 131, 132), dendritic cells (DC) (133, 134), and natural killer (NK) cells (135-138) have been shown to perform trogocytosis. B cells acquire tethered antigen from target cells via trogocytosis (132). *In vivo* studies have shown that DCs can capture MHC class I and II from other DCs (133, 134), and NK cells can acquire MHC class I *in vitro* and *in vivo* (135, 136, 138), along with membrane (137) from target cells. The requirements for trogocytosis by these cells appear to be less stringent than it is for T cells. B cells can perform trogocytosis without BCR signaling and can acquire molecules from dead or lysed cells (111, 129). Similarly DC have been shown to acquire MHC class I from apoptotic or necrotic tumor cells (139, 140), whereas T cells trogocytosis requires an intact APC (129). Unlike T cells, trogocytosis by NK, B, and DCs can does not require Ag recognition (111, 129, 139, 141).

The acquisition of APC-derived molecules via the immune synapse can be monitored using fluorescent microscopy, using fluorescently conjugated antibodies and tagged surface molecules. In fig. 6, live-cell microscopy images show the formation of several immune synapses, which can be seen as the accumulation of GFP-tagged
MHC:peptide at the T-APC interface. As each of the three T cells dissociate from the APC, the GFP:pMHC is trogocytosed onto the T cells (103).

Figure 6. CD4$^+$ T cell trogocytosis via the immunological synapse. Time-lapse images showing immune synapse formation and upon dissociation from APC the T cell trogocytoses MHC:peptide. AD10 T cells were placed in culture with GFP-tagged MHC:peptide and live cell imaging was performed for the times shown above. GFP (green) is overlaid on DIC images (blue). From Wetzel et al. (103).

Molecules Trogocytosed and requirements for T cell trogocytosis

The process of trogocytosis occurs via the immune synapse in NK, B, and T cells, but only in T cells is the synapse and signaling an integral part of trogocytosis (103, 111, 129, 139, 141). Through the immune synapse, T cells trogocytose molecules from the c-SMAC, p-SMAC, and the d-SMAC. Among these are: costimulatory molecules
including CD80 (103, 130, 142), CD86 (106), OX40 ligand (143), and programmed death ligand 1 (144), adhesion molecules [including ICAM-1 (111)], and MHC:peptide complexes (103, 105-107, 119, 145-147). Also, T cells can acquire membrane lipids from the APC via the immune synapse (88, 107, 148).

Trogocytosis of membrane and membrane-bound molecules can also be measured using flow cytometry analysis. Fig. 7 shows histograms of CD4⁺ T cells recovered from fibroblast APCs that had myristoylated-CFP membrane. In the left histogram, cells were antibody stained for trogocytosed MHC:peptide, and in the right histogram the trogocytosis of myristoylated-CFP-tagged APC plasma membrane is shown. The solid line represents T cells that were co-cultured with the myristoylated-CFP containing APCs. Both show a shift in the staining intensity for trogocytosed MHC:peptide and CFP membrane compared to the unstimulated sample (dotted line). These data show that one can monitor trogocytosis, such as the intercellular transfer of membrane proteins, along with plasma membrane using flow cytometry.
As mentioned above, an integral component of T cell trogocytosis is the engagement of the TCR by MHC:peptide (103, 111, 129). In the absence of TCR engagement, trogocytosis is significantly reduced or halted (103, 106, 122). Hudrisier et al. found that by blocking the initiation of TCR signaling using the Src kinase inhibitor, PP2, also blocked trogocytosis (107); as TCR signaling increased, trogocytosis also increased (107, 123), and that latruculin B, an inhibitor of actin polymerization, inhibits trogocytosis by T cells (107).

Our lab and others have shown that the amount and the specificity of the Ag being presented effects trogocytosis efficiency (103, 105-107, 119, 130, 142, 146, 149).
Trogocytosis efficiency is significantly lower in the absence of peptide (105-107) and is dose dependent (103, 105, 107, 130, 142). Wetzel et al. also found that CD4⁺ T cell trogocytosis is peptide specific (103). Several other papers have confirmed that peptide specificity plays a role in trogocytosis (105, 107, 146).

Costimulatory molecules also play an important role in T cell trogocytosis. Using blocking antibodies or CD28−/− T cells, Hwang et al. found that T cells require interactions with costimulatory molecules, like CD80, on the APC for TCR mediated trogocytosis to occur (106). Their data give support to the hypothesis that the immune synapse is essential for trogocytosis, as it has been shown that CD80 is required for mature immune synapse formation (78, 150, 151).

The activation state of the T cell plays an important role in trogocytosis. One of the earliest T cell trogocytosis papers discovered that activated T cells performed trogocytosis better than naïve T cells (152). Since then, many others have found that resting or naïve T cells have reduced trogocytosis capabilities compared to activated T cells (104, 106, 124, 130, 142, 153). Hwang et al. and others have hypothesized that the increased expression of CD28 by activated T cells leads to increased adhesion that could result in this difference (106, 122, 130). Consistent with this hypothesis, activated T cells increase expression of their adhesion molecules, such as CD44 (31, 33), which could also lead to increased trogocytosis.
The mechanism of trogocytosis from APC to T cell remains unclear. Early data established that trogocytosis occurred via transsynaptic capture or directly from the immune synapse (120, 123). Using electron microscopy, Patel et al. observed that APC derived exosomes, which subsequently fused with the T cell, localized to the space between the T cell and the APC (120). Another method of transsynaptic capture was discovered by Stinchcombe et al., where they showed that upon dissociation of a cytotoxic T lymphocyte (CTL) from its’ target cell, small “membrane bridges” had formed between the cells (88). Resolution of the bridges lead to the transfer of MHC class I and YFP-tagged membrane onto the T cell from the APC (88).

More recently, TCR downmodulation and coincidental phagocytosis has been proposed as a mechanism for T cell trogocytosis. In 2011, Martin-Martin et al. found that phagocytic mechanisms, specifically involving the activity of the small GTPases TC21 and RhoG, drive TCR downmodulation at the c-SMAC (20). This is consistent with earlier data from Lee et al. and Cemerski et al., showing the TCR is downmodulated at the c-SMAC (98, 154) and with the finding of Huang et al., who showed that CD8\(^+\) T cells also perform trogocytosis by TCR downmodulation (105). These phagocytosed APC membrane fragments are delivered to endosomes (105) and it has been hypothesized that they fuse with the endosome membrane and upon recycling to the plasma membrane, the APC molecules are integrated into the T cell membrane in their native topology (20, 155). This model is depicted in fig. 8 (155).
Integration of trogocytosed molecules into the T cell plasma membrane

Imaging data by Wetzel et al. helped to confirm that trogocytosed molecules are integrated into the T cell plasma membrane. They showed that only after detergent permeabilizing the T cell membrane could they stain for the cytoplasmic GFP tail on trogocytosed GFP-tagged MHC:peptide (103). Other results from our lab also suggest that trogocytosed molecules are integrated into the T cells plasma membrane (fig. 9). After recovery of T cells from an in vitro trogocytosis assay, anti-I-E\(^{k}\) (I-E\(^{k}\) is the murine MHC class II) was added and the amount of trogocytosed GFP-tagged MHC:peptide was monitored over time. If the trogocytosed material were tethered, we would expect the antibody to disrupt and release the molecules from the surface of T cells, leading to a loss of GFP. In fig. 9, after 1 hr and up to 24 hrs with anti-I-E\(^{k}\), there is still significant GFP on the surface of the recovered T cells (black line) suggesting the molecules have been integrated into the membrane. The presence of captured MHC:peptide and costimulatory molecules on the T cell surface, as a result of trogocytosis, suggests several potential roles for these molecules in T cell biology.
Figure 8. Proposed mechanism for trogocytosis. Two proposed mechanisms for TCR downmodulation. One occurs via clathrin dependent mechanisms in the p-SMAC and the second occurs via phagocytic mechanisms in the c-SMAC. The TCR internalization in the c-SMAC leads to the trogocytosis of APC molecules that are then re-expressed on the T cell surface. From Dopfer et al. (155).
Figure 9. Trogocytosed molecules are integrated into the T cell membrane. After a 90 min co-culture with fibroblast APC, T cells were recovered and placed in culture with an antibody to I-E^k. Aliquots were taken at 1, 8, and 24 hours and stained for I-E^k. T cells with anti-I-E^k (black line) show higher levels of I-E^k staining compared to unstimulated T cells (shaded histogram) and similar to recovered T cells without anti-I-E^k (dotted line). (unpublished data by Dr. Scott Wetzel)
The function of trogocytosis

The biological significance of trogocytosis on CD4+ T cells remains unclear. The potential role of trogocytosis in modulating immune responses falls into two broad categories: cell extrinsic and cell intrinsic. Extrinsic function relates to how the trogocytosis+(trog+) T cell interacts with surrounding immune cells. The fact that trogocytosed molecules, including MHC:peptide and costimulatory molecules, are integrated into the T cell membrane in the correct orientation suggests that the trog+ T cell may be able to present Ag (103, 107). As detailed below, several studies have observed that Ag presentation by trog+ T cells can modulate the activation of responding T cells (146, 147, 156-160) (T-T Ag presentation). The intrinsic cellular function of trogocytosis relates to how trogocytosed material directly affects the individual trog+ T cell biology. The few studies that have been done have shown that the trogocytosed material may continue to interact with surface receptors on the trog+ T cell leading to continued activation and signaling in the absence of APC, a process called autopresentation (103, 161).

Trog+ T cells as APCs

The presence of trogocytosed MHC:peptide and CD80 on the T cells has been shown in many studies to be involved in T cell to T cell Ag presentation (105, 107, 120, 130, 146, 150, 158, 159, 162-164). Analysis of T-T presentation first started in the 1970’s with human T cells that endogenously express MHC class II, could be used to present Ag to other human T cells (165-174). The vast majority of these studies found that Ag
presentation by human or rat CD4^+ T cells (which also endogenously express MHC class II) leads to the induction of anergy in the responder T cells (165-167, 169-174). The induction of anergy in these responder T cells is likely due to a lack of costimulation on the surface of the presenting T cells. Of these studies, only two looked at T cell presentation of trogocytosed molecules (166, 168). One of the studies showed that CD4^+ T cells could pick up antigens of gp120, an HIV receptor, during Ag presentation with an infected T cell and use the antigens to help in the spread of HIV (168).

To study potential T-T Ag presentation as a result of trogocytosis, murine CD4^+ T cells are typically used because they don’t endogenously express MHC class II (175). Several papers have examined the presentation of trogocytosed molecules by CD4^+ T cells (158, 159, 176). The initial studies of CD4^+ T cell trogocytosis and subsequent T-T presentation showed CD4^+ T cells presenting trogocytosed bystander MHC class I molecules and costimulatory molecules to CD8^+ T cells (147, 177, 178). Xiang et al. showed that CD4^+ trog^+ T cells can acquire bystander p:MHC class I with p:MHC class II at the synapse and act like T_H1 cells and activate CD8^+ T cells (147). The CD4-CD8 interaction leads to the clonal expansion and generation of effector functions in the CD8^+ T cells (147, 156, 177, 178). However, in the majority of trogocytosis-related studies, CD4-CD8 and CD4-CD4 Ag presentation have found that T-T presentation is a regulatory mechanism for inducing apoptosis, CTL killing (146, 178) or anergy (146, 158, 159, 179) in the responder T cells. Helft et al. found T-T presentation regulated responder T cells by inhibiting effector/memory cell activation, but allowed for naïve T cell survival (158). Most recently, Zhou et al. found that by adoptively transferring trog^+ T_H into TCR transgenic mice, the trog^+ T_H cells presented Ag to naïve T cells (159); this
increased CD25 expression in the responder. In contrast, when trog\textsuperscript{T} T\textsubscript{reg} cells were added with the effector cells, CD25 expression went down (159). These studies suggest that T cell Ag presentation has different effects on effector/memory cells and naïve T cells.

**Trogocytosis intrinsic function**

The presence of trogocytosed molecules may also have an effect on the biology of the individual trog\textsuperscript{T} T cell. The presence of captured MHC:peptide and costimulatory molecules on T cells suggests the possibility of autopresentation, wherein the trogocytosed molecules on the surface of the T cell continue to engage receptors leading to signaling in the absence of APCs. Zhou et al. first studied the effects of autopresentation of CD4\textsuperscript{T} T cells, by looking at the effects of antigen-presentasomes (APS), small exosomes derived from an APC tethered to the surface of T cells (161). They found that T cells with APC derived vesicles or APS attached to their surface, had increased levels of transcription factors NF\textsubscript{κ}B and AP-1 which lead to proliferation and activation of the T cells in the absence of APC (161). However this study did not determine if the APS were responsible for signaling or if they just marked the cells that were signaling. In addition, this study did not involve actual “trogocytosis” because trogocytosis leads to the integration of trogocytosed molecules (103, 104, 152) and is not APC derived vesicles or APS tethered to the T cell surface (103, 155). Their experimental setup also strongly favored T-T presentation (161), casting further doubt on their results.

The study done by Wetzel et al. in 2005 was the first to examine signaling from trogocytosed molecules (103). Using fluorescent microscopy, they found that several TCR-associated signaling molecules, including phosphorylated tyrosine (pTYR) and Lck,
colocalized with the trogocytosed molecules on the surface of T cells recovered from APC (103). Their data suggest that there is sustained signaling occurring in the T cell due to autopresentation or continued engagement of the TCR with the trogocytosed molecules (103). Wetzel et al. and Zhou et al. studies were the only studies prior to the work detailed in this thesis analyzing intracellular signaling in trog^+ CD4^+ T cells.

Autopresentation of trogocytosed molecules may play a role in signal “summing” (180) [i.e. repeated short-duration encounters that have been observed in T cell activation (181, 182)]. By continually engaging the TCR with trogocytosed MHC:peptide molecules may sustain intracellular signaling leading to continual activation, proliferation, and survival. An unresolved question regarding this potential autopresentation is whether trog^+ T cells sustain signaling over time without the presence of APC and whether the sustained signaling is induced by the trogocytosed material, examining this question is the main focus of this thesis.
Rationale

The impact of trogocytosis on the biological function of T cells is unclear. In this thesis, I have examined the effects of trogocytosis on the individual trog^+ CD4^+ T cell. The goal of these experiments was to determine the role trogocytosis plays in CD4^+ T cell activation, sustained signaling, proliferation, and selective survival in the trog^+ T cells. A murine fibroblast cell line expressing an I-E^k molecule loaded with a covalently attached antigenic peptide (moth cytochrome C_{88-103}) and containing a GFP-tagged cytoplasmic tail was used as surrogate APCs and for T cells a peptide-specific TCR transgenic mouse was used. The GFP-tagged MHC:peptide on the APCs allows for the monitoring of trogocytosis by the presence of GFP on the surface of the T cells. Trogocytosis can also be monitored by antibody (Ab) staining, because murine T cells do not express MHC class II. Using a combination of high-resolution microscopy and flow cytometry, it was observed that the trogocytosed material is retained on the surface of the T cell.

The first aim was to determine what is required for the initial trogocytosis of molecules by T cells. Multiple studies have found that naïve T cells perform trogocytosis at reduced levels compared with activated T cells (104, 106, 124, 130, 142, 153), but none have looked at whether the initial interaction of the naïve T cell with APC leads to trogocytosis. Naïve T cells from AND x Rag-1^−/− mice (mice with APCs that lack I-E^k) were used to determine if the initial Ag presentation was sufficient enough to induce significant trogocytosis. The data shows whether trogocytosis leads to the activation, proliferation, and selective survival of trog^+ CD4^+ T cells. Flow cytometry data will show
whether trog\textsuperscript{+} T cells have an activated phenotype, proliferate, and survive longer in culture following recovery from APCs compared to trog\textsuperscript{-} T cells.

The second aim was to assess whether trogocytosis leads to sustained signaling. Both Zhou \textit{et al.} and Wetzel \textit{et al.} have shown that signaling occurs in trog\textsuperscript{+} T cells (103, 161), but neither has determined if the signaling persists over time in the absence of APC. Using wide-field microscopy, colocalization of several TCR associated-signaling molecules with the trogocytosed material was analyzed. Using flow cytometry, sustained signaling in trog\textsuperscript{+} T cells, over several days, in the absence of APC to see if sustained signaling remained in trog\textsuperscript{+} T cells and not in trog\textsuperscript{-} T cells.

The final aim of this thesis was to determine whether sustained signaling observed in trog\textsuperscript{+} T cells, is driven by the trogocytosed molecules. Zhou \textit{et al.} showed that having tethered trogocytosed molecules on the T cell surface correlated with signaling in the trog\textsuperscript{+} T cells (161), but they did not address if the trogocytosed molecules were responsible for the signaling. Using an inhibitor to TCR signaling, PP2, the role of trogocytosis in sustained signaling was examined. Using cultures of recovered T cells, PP2 was added for 10 min, duration long enough for TCR signaling inhibition, then washing out the inhibitor and incubate for 20 min to allow signal reinitiation. If TCR signaling rebounds it suggest there is continual engagement of the TCR by the trogocytosed material. Both flow cytometry and fluorescent microscopy data will determine if there is rebound in TCR signaling following removal of PP2 in recovered trog\textsuperscript{+} T cells.

I conclude by showing preliminary T-T presentation data. Experiments were set up, using FACS sorted trog\textsuperscript{+} AD10 T cells placed in culture with naïve AND x B10.BR T
cells, to determine if trog$^+$ T cells present Ag to the naïve T cells. Ag presentation was confirmed by the activation of the naïve T cells by staining for activation markers (i.e. CD69 and CD25) using flow cytometry.

The findings from this dissertation will further help to elucidate the biological role of trogocytosis on CD4$^+$ T cells by showing that trogocytosis leads to sustained signaling, proliferation, and selective survival of trog$^+$ T cells. The data in this thesis suggest a possible role for trogocytosis in an immune response.
Chapter 2:

Materials and Methods

Animals

Heterozygous AD10 TCR transgenic mice (Vβ3+), specific for pigeon cytochrome c fragment 88–104 (183) and reactive against moth cytochrome c (MCC) fragment 88–103 on a B10.BR (H-2k) background, were kindly provided by S. Hedrick (University of California, San Diego, CA) by way of David Parker (OHSU, Portland, OR). This strain was maintained as heterozygotes by breeding to B10.BR mice, and transgenic mice were identified by PCR. Homozygous AND x Rag-1−/− TCR transgenic mice were purchased from Jackson Laboratory (Bar Harbor, Maine). AND x Rag-1−/− mice were maintained as homozygotes. Heterozygous AND x B10.BR TCR transgenic mice were bred in the University of Montana Laboratory Animal Resources facilities. Only F1 animals resulting from breeding homozygous AND x Rag-1−/− mice with B10.BR mice were used in experiments. Mice were housed in the University of Montana Laboratory Animal Resources facilities and were allowed food and water ad libitum. All procedures were supervised and in accordance with the University of Montana IACUC.

Antibodies and staining reagents

The following conjugated or unconjugated Abs were purchased from BD Pharmingen (San Jose, CA): anti-TCR Vβ3 (clone KJ25), anti-ZAP70 PO4 (Y319 ; clone 17 A/P-ZAP-70), anti-ERK PO4 (MAPK p44/42 T202/Y204; clone 20a). CFSE, chicken anti-rabbit IgG AlexaFluor 647, AlexaFluor 647-conjugated streptavidin, Pacific Blue-
conjugated streptavidin, AlexaFluor 488-conjugated streptavidin, and Vybrant® CM-DiI cell solution were purchased from Life Technologies (Eugene, OR). Biotin conjugated anti-phosphotyrosine (4G10) was purchased from Upstate Biotechnology (Lake Placid, NY). Rabbit polyclonal antibodies specific for phosphorylated Lck (Y505; #2751) and phosphorylated ZAP-70 (Y319 Syk PO₄ Y352; #2701) along with a mouse IgG1 monoclonal anti-phosphorylated ERK 1/2 (MAPK p44/42 T202/Y204; #E10) were purchased from Cell Signaling Technology (Beverly, MA). Secondary staining reagents, including Aminomethylcoumarin Acetate (AMCA)-conjugated streptavidin, Cy5-conjugated polyclonal goat anti-armenian hamster IgG H+L, Texas Red-conjugated polyclonal goat anti-armenian hamster IgG H+L, Texas Red-conjugated polyclonal donkey anti-rabbit IgG H+L, and Texas Red-conjugated anti-mouse IgG H+L were purchased from Jackson ImmunoResearch Laboratories (West Grove, PA). Purified anti-CD3 (145.2C11), along with fluorescently conjugated anti-CD69 (H1.2F3), anti-CD4 (RM4-5), anti-C25 (PC61), anti-CD11c (N418), anti-F4/80 (BM8), and CD80 (16-10A1) were purchased from BioLegend (San Diego, CA). PE-conjugated anti-CD45R (B220) (RA3-6B2) was purchased from eBioscience (San Diego, CA). Anti-I-EkB (17-3-3) was purchased from Southern Biotechnology (Birmingham, AL). EZ-link® Sulfo-NHS-biotin (sulfosuccinimidobiotin) to label the cell surface was purchased from Pierce (Rockford, IL).

**Antigen presenting cells**

MCC:GFP fibroblasts expressing enhanced GFP-tagged I-EkB β-chain with covalently attached antigenic MCC₈₈₋₁₀₃ were described previously (184). A second
transfected fibroblast line, MCC:FKBP, has the MCC:I-E\(^k\) \(\beta\)-chain fused to three repeats of the FK506-binding protein (FKBP) (Ariad Pharmaceuticals, Cambridge, MA) in place of the GFP tag (103). The MCC:GFP and MCC:FKBP express nearly identical levels of CD80, ICAM-1 and surface MCC:I-E\(^k\). A third transfected fibroblast cell line, P13.9H expresses CD80 and ICAM-1 similar to the other fibroblast cell lines, but it expresses I-E\(^k\) without antigenic peptide attached. P13.9 cells were provided by Dr. Ron Germain (NIAID, National Institutes of Health). Cells were maintained in “complete DMEM” containing high glucose DMEM (Life Technologies, Carlsbad, CA) supplemented with 10% FBS (Atlanta Biologicals, Atlanta, GA), 1 mM L-glutamine, 100 mg/ml sodium pyruvate, 50 \(\mu\)M 2-ME, essential and nonessential amino acids (Life Technologies, Carlsbad, CA), 100 U/ml penicillin G, 100 U/ml streptomycin, and 50 \(\mu\)g/ml gentamicin (Sigma, St. Louis, MO.).

**In vitro T cell priming**

Single cell suspensions of splenocytes from 6- to 12-wk-old AD10 transgenic mice or AND x B10.BR F\(_1\) mice were depleted of erythrocytes by hypotonic lysis in Gey’s solution and resuspended in “complete RPMI” containing RPMI (Life Technologies) supplemented with 10% FBS (Atlanta Biologicals, Atlanta, GA), 1 mM L-glutamine, 100 mg/ml sodium pyruvate, 50 \(\mu\)M 2-ME, essential and nonessential amino acids (Life Technologies), 100 U/ml penicillin G, 100 U/ml streptomycin, and 50 \(\mu\)g/ml gentamicin (Sigma, St. Louis, MO.). Cells were used directly ex vivo or were activated in vitro for 6 days by addition of 2.5 \(\mu\)M MCC\(_{88-103}\) peptide to splenic cell suspensions at \(~4 \times 10^6\) cells/ml. Lymphocytes were isolated from priming cultures by density
centrifugation using Lympholyte M (Cedarlane Laboratories, Burlington, NC). T cells were resuspended at $5 \times 10^6$/ml in phenol red-free complete RPMI and kept at 4°C until used.

**Standard in vitro trogocytosis assay**

To assess trogocytosis by the CD4$^+$ AD10 T cells, we used our previously described standard *in vitro* trogocytosis assay (103). Briefly, $1 \times 10^6$ MCC:GFP or MCC:FKBP cells were plated into individual wells of a six-well tissue culture plate (Greiner, Monroe, NC) and incubated overnight at 37°C. For cell surface labeling and to measure trogocytosis, either $2.5 \times 10^7$ MCC:GFP or MCC:FKBP cells/ml were placed in PBS (pH 8.0) and stained using 10 mM solution of EZ-link® Sulfo-NHS-biotin at room temperature for 30 min. These cells were washed three times in PBS with 100 mM glycine, resuspended in DMEM, and then plated at $10^6$/well. In some experiments, 5 μM Vybrant® CM-DiI cell solution was also used to stain the cell surface of MCC:GFP or MCC:FKBP. For this staining, 5 μl/ml of CM-DiI was added to $10^6$ MCC:GFP or MCC:FKBP cells/ml in Hank’s Balanced Salt Solution (HBSS, Life Technologies) for 20 min at 37°C, washed in complete DMEM, and then the cells were incubated overnight at 37°C. A total of $2.5 \times 10^6$ *in vitro* primed T cells were added to each well and the plates were centrifuged briefly (30 seconds at 200 x g) to promote T-APC interaction. The cells were then incubated for 90-minutes at 37°C. After the 90-minute incubation, T cells were recovered from the cultures by rinsing with PBS. No additional dissociating reagents were added (e.g., EDTA or trypsin) to aid in T cell recovery. In this way, only cells that had spontaneously dissociated from the APC were collected. After two PBS washes,
recovered T cells (containing both trogocytosis\(^+\)(trog\(^+\)) and trogocytosis\(^-\)(trog\(^-\))) were used immediately in microscopy or flow cytometry experiments, or were resuspended in complete RPMI at very low density (10\(^4\)/ml) and cultured for additional times up to 6 days. At the end of the incubation period, cells were resuspended at 10\(^6\)/ml before staining and fixation for flow cytometry experiments or addition to poly-L-lysine-coated LabTek II chambered coverslips for imaging, as described below.

**In vitro naïve T cell trogocytosis assay**

To assess trogocytosis by naïve T cells, AND x Rag-1\(^{-/-}\) mice were used. In these experiments, 1 x 10\(^6\) biotin labeled MCC:FKBP cells were plated into individual wells of a six-well tissue culture plate (Greiner, Monroe, NC) and incubated overnight at 37°C. A total of 2.5 x 10\(^6\) AND x Rag-1\(^{-/-}\) T cells were added to each well and the plates were centrifuged briefly (30 seconds at 200 x g) to promote T-APC interaction. The cells were then incubated for 6-24 hours at 37°C. After the 6-24 hour incubation, T cells were recovered from the cultures by rinsing with PBS, as described for the standard trogocytosis assay. Similar to the standard trogocytosis assay, after two PBS washes, recovered T cells (containing both trog\(^+\) and trog\(^-\)) were used immediately in microscopy or flow cytometry experiments or were resuspended in complete RPMI at very low density (10\(^4\)/ml) and incubated for additional times up to 6 days. In some experiments, after 2 days T cells were restimulated using fresh biotin-labeled MCC:FKBP cells using the standard *in vitro* trogocytosis assay described above. To differentiate between trogocytosis that occurred in the primary stimulation compared to the restimulation, two different secondary staining reagents were used: AF488-conjugated and AF647-
conjugated streptavidin. Prior to the restimulation, T cells were stained with AF488-conjugated streptavidin to identify biotin that had been trogocytosed from the primary stimulation. Following the restimulation, the T cells were stained with AF647-conjugated streptavidin to identify biotin trogocytosis from the restimulation culture.

**Flow cytometry**

Cells were recovered from the cultures and resuspended at $10^6$/ml in FACS buffer (PBS, pH 7.4 containing 2% BSA Fraction V (Sigma) and 0.1% NaN$_3$). The T cells were stained with the indicated reagents for 30-minutes at 4°C in FACS buffer. When necessary, after three washes, cells were stained for 20-minutes with secondary reagents in FACS buffer. To measure activation, cells were stained for the activation marker CD69 and CD25, along with the TCR (V$\beta$3) and CD4. Following a final set of three washes in FACS buffer, cell were resuspended in 500µl of FACS buffer and stored on ice protected from light until analyzed using a FACS Aria II (BD Biosciences) in the UM Fluorescence Cytometry Core. Alternatively, after the final wash cells were fixed by addition of ice-cold fixative (4% paraformaldehyde and 0.5% glutaraldehyde) followed by a 45-minute incubation at room temperature. Following an additional set of FACS buffer washes, cells were resuspended in 500µl FACS buffer and were stored at 4°C in the dark for up to 3 days until analysis. To examine proliferation, cells were labeled with 5 mM CFSE in PBS prior to establishment of the *in vitro* priming cultures.
Examination of trogocytosis associated intracellular signaling by flow cytometry

To assess the activation state of TCR proximal (ZAP-70) and distal (ERK) intracellular signaling molecules, we modified the phosphorylation (phosflow) protocol of Chow et al. (185). After staining surface molecules on live cells, as described above, cells were fixed for 10-minutes in ice-cold fixative (4% paraformaldehyde and 0.5% glutaraldehyde in PBS). After two washes in PBS plus 5% FBS, cells were permeabilized/fixed for between 10-30 minutes with ice-cold 50% methanol in PBS and washed twice in PBS prior to staining. Cells were then stained with primary staining reagents for 30 min at 4°C in FACS buffer at a 1:100 dilution (2 µg/ml). After three washes, cells were stained for 20-minutes with secondary reagents in FACS buffer at a 1:200 dilution (2 µg/ml). After a final set of washes, cells were analyzed immediately or were stored at 4°C for up to 3 days before analysis on a FACS Aria II. Data were analyzed with FlowJo 8.8.7 software (Tree Star, Ashland, OR) on a Macintosh iMac (Apple, Inc). As a positive control, AD10 T cells were activated using phorbol 12-myristate 13-acetate (PMA) (Sigma, St. Louis, MO.) or anti-CD3 (145-2C11). For PMA stimulation, following a 6 day in vitro T cell priming, 40 nM PMA was added to the cells for 10 min at 37°C, and then washed out immediately before the cells were stained. For anti-CD3 stimulation, following a 6 day in vitro T cell priming, 5 µg/ml anti-CD3 was added to the cells in solution for 30 min at 4°C. Following a wash with PBS, 10 µg/ml Texas Red-conjugated polyclonal goat anti-armenian hamster IgG H+L was added for 15 min at 4°C to cross-link the anti-CD3, unbound Ab washed out before the cells were stained.
**Immune synapse microscopy**

To examine the immune synapse, one day prior to imaging 2.5 × 10^4 MCC:GFP cells were added per well in #1.5 LabTek II eight-chambered coverslips (Nunc, Rochester, NY) and incubated overnight at 37°C. The next day 10^5 T cells were added to each well and the dishes were spun at 200xg for 30 sec to initiate contact between T cells and APCs. After a 30-minute incubation at 37°C, cells were fixed by addition of ice-cold fixative (4% paraformaldehyde and 0.5% glutaraldehyde in PBS) and incubated for 45-minutes at room temperature in the dark followed by permeabilization with 0.2% Triton X-100 in PBS for 10-minutes. Cultures were stained with primary Abs at concentrations of 10 µg/ml in imaging buffer (PBS plus 2% BSA Fraction V) for 2 h at room temperature in a humidified chamber. After three 5-min PBS washes, cells were incubated with secondary Abs (1:200 dilution in imaging buffer) for 2 h at room temperature. After three additional PBS washes, SlowFade Gold antifade reagent (Life Technologies) was added to the wells. Samples were stored at 4°C and protected from light until imaged.

T cell–APC conjugates to be imaged were chosen based upon their characteristic morphology in differential interference contrast (DIC) of T cells in tight contact with and flattened against an APC. A stack of 50–90 fluorescent images spaced 0.2 µm apart in the z-axis was obtained with a 60X, 1.4 NA, oil immersion lens on the Applied Precision (API) DeltaVisionRT image restoration microscopy system (Issaquah, WA).
**Microscopic analysis of trogocytosis**

To examine trogocytosis by microscopy, T cells were recovered from the standard *in vitro* trogocytosis assay after the 90-minute incubation by vigorous rinsing with PBS. Cells were immediately stained or incubated for up to 72 hrs before staining. For imaging of cells directly from the trogocytosis assay, $10^6$ recovered T cells were placed in each well of Poly-L-Lysine pre-coated #1.5 LabTek II eight-chambered coverslips for 10-minutes at 37°C. For time course experiments, recovered T cells (containing both trog$^+$ and trog$^-$) were incubated at very low density ($10^4$/ml) for the indicated times before being placed in the Poly-L-Lysine coated chambered coverslips. Cells were fixed by addition of ice-cold fixative (4% paraformaldehyde and 0.5% glutaraldehyde in PBS) and incubated for 45-minutes at room temperature in the dark followed by permeabilization with 0.2% Triton X-100 in PBS for 10-minutes. Cells were antibody stained as described above, then imaged using an Applied Precision DeltaVisionRT microscopy system (Issaquah, WA). Cells were chosen for imaging in DIC by identifying isolated, individual T cells in the field (and without regard to potential fluorescence). T cells were imaged in the same manner as the T-APC conjugates, as described above.

**Image analysis**

Constrained, iterative deconvolution was performed using the API SoftWorx software package. Using SoftWorx the integrated intensity of GFP, which is a measure of the amount of fluorescently-labeled molecules accumulated, was obtained for areas $\geq 2$-fold above background fluorescence. Background fluorescence was measured using a region of interest (ROI) that encompassed areas away from the cell. For the analysis of
phosphorylated signaling molecules, the integrated intensity and mean fluorescent intensity was obtained for areas ≥6 fold above background, again using ROI to measure background, unless otherwise noted. Maximum intensity projections (MIP) were used to create three-dimensional (3D) reconstructions for image analysis using the API SoftWorx software. Line profiles were used to measure pixel intensity and distances using the API SoftWorx software. For both recovered T cells and T-APC conjugates, 20-25 cells or conjugates were imaged for each treatment group in each of the six experiments. Integrated intensity and mean fluorescence intensity (MFI) were measured using single optical sections. Both MFI and integrated intensity were measured using ROIs that encompassed the trogocytosed molecules or intracellular signaling molecule. Co-localization between trogocytosed molecules and intracellular signaling molecules was assessed by the Pearson’s correlation coefficient and overlap coefficients using the JACOP plug-in (186) in ImageJ (187).

**TCR signaling inhibition**

To determine if sustained signaling was due to engagement of the TCR by trogocytosed material, TCR signaling inhibition experiments were performed similar to those of Faroudi et al. (188). Cells incubated at very low density ($10^4$/ml) were treated for 10 or 30 minutes with 20 µM PP2, a Src-family tyrosine kinase inhibitor (189) (Life Technologies). Three treatment groups were set up for the TCR signaling inhibition experiments. In the first group, cells were incubated for 30-minutes in media only to serve as an untreated control. In the second group, cells were incubated with 20µM PP2 for 10-minutes followed by three washes to remove the PP2. Cells were incubated for 20
additional minutes in media. In the final positive-control group, cells were incubated for 30-minutes in the presence of 20µM PP2, to confirm that the PP2 treatment inhibited both TCR proximal and distal signaling events. After incubation, cells were fixed and stained for phosphorylated ZAP-70 (TCR proximal signaling) and phosphorylated ERK 1/2 (TCR distal signaling) for flow cytometry and imaging, as described above.

**T-T presentation**

To examine the potential of trog+ T cells to present Ag, trog+ T cells were FACS sorted and incubated with naïve AND x B10.BR T cells as potential responders. To generate the trog+ cells, AD10 T cells were incubated with surface biotinylated and CFSE stained MCC:FKBP cells in the standard *in vitro* trogocytosis assay. The CFSE stain and lineage markers were used to identify and remove fibroblast, other contaminating cells. Biotin+ CFSE− (trog+) and biotin− CFSE− (trog−) T cells were sorted using the FACS Aria II in the UM Fluorescence Cytometry core. The cultures were also stained for the following lineage markers, B220 (B cells), F4/80 (Mφ), CD11c (DC). For each of the four experiments performed, ~10^7 trog+ and trog− T cells were collected. To assess sort purity, 10^6 trog+ and trog− T cells were stained with PerCP-conjugated anti-CD4 and analyzed by flow cytometry. To assess the ability of the trog+ and trog− cells to present Ag, the sorted trog+ or trog− T cells were placed in culture with CFSE-labeled naïve AND x B10.BR T cells at a 1:1 ratio overnight at 37°C. The CFSE staining allowed for identification of the naïve T cells. After the overnight coculture, T cells were recovered, stained, and analyzed using flow cytometry. CFSE+ and CFSE− cell populations were compared using stains for activation markers CD69 and CD25, and trogocytosed biotin.
Peptide affinity

To assess whether antigenic peptide affinity affects trogocytosis by either CD4\(^+\) AD10 or AND x B10.BR T cells, we used our previously described standard *in vitro* trogocytosis assay (103). Briefly, P13.9H cells were plated at 10\(^6\)/well into individual wells of a six-well tissue culture plate and incubated overnight at 37°C with peptides. Three peptides with varying TCR affinity were loaded onto P13.9H cells: a high-affinity agonist peptide MCC (ANERADLIALKQATK) (Sigma, Woodlands, TX), intermediate-affinity peptide MCC-A (AAAAAAAAYAYAKQATK) (New England Peptide, Gardner, MA), or a very weak agonist altered peptide ligand MCC-K99A (ANERADLIALQATK) (Sigma, Woodlands, TX). During the initial plating of the P13.9H cells, 2.5 \(\mu\)M of each peptide was added to the cell cultures. A total of 2.5 \(\times\) 10\(^6\) *in vitro* primed T cells were added to each well and the plates were centrifuged briefly (30 seconds at 200 x g) to promote T-APC interaction. The cells were then incubated for 90-minutes at 37°C. After the 90-minute incubation, T cells were recovered from the cultures by rinsing with PBS. No additional dissociating reagents were added (e.g., EDTA or trypsin) to aid in T cell recovery. In this way, only cells that had spontaneously dissociated from the APC were collected. After two PBS washes, recovered T cells (containing both trogocytosis\(^+\) (trog\(^+\)) and trogocytosis\(^-\) (trog\(^-\))) were used immediately in flow cytometry experiments. Recovered T cells were resuspended at 10\(^6\)/ml before staining and fixation for flow cytometry experiments, as described above.
Quantitative RT-PCR was used to analyze the differences in gene expression between trog⁺ and trog⁻ T cells. Using the same cell sorting technique as described above, 10⁶ trog⁺ and trog⁻ T cells were placed in 1 ml Trizol overnight at 4°C to digest the cells and to recover mRNA and then sent to the Molecular Biology core at the University of Montana to perform qRT-PCR on the BioRad iCycler 5 (Hercules, CA). qRT-PCR was run using selected primers, shown in Table 1. Primers for T cell cytokines, IL-2, IFNγ, IL-4, expression were used to determine which T cell subsets, Th1 or Th2 performed trogocytosis. Primers for pro-apoptosis molecule Bad and anti-apoptotic molecule BCL2, were used to determine if there is an increase or inhibition of apoptosis. Primers for cell cycle molecules p27Kip1, which is involved in G1 cell arrest, c-Fos, and cyclin D2, which play a role in cell cycle progression, were used to determine if the cells are preparing for proliferation. Primers were purchased from Integrated DNA Technology (Coralville, IA). Data was returned from the core and analyzed by the ΔΔCt method to determine fold changes in gene expression using Microsoft Excel.

Table 1. qRT-PCR primer sets:

<table>
<thead>
<tr>
<th>Gene</th>
<th>5’ Primer</th>
<th>3’ Primer</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-2</td>
<td>GCTGTGATGGACCTACAGGA</td>
<td>TTCAATTCTGTGGCCTGTT</td>
</tr>
<tr>
<td>IFNγ</td>
<td>ATCTGGAGAACTGCAAATAA</td>
<td>TTCAAGACTTCAAGAGTCTGAGG</td>
</tr>
<tr>
<td>IL-4</td>
<td>GAGAGACCATCGCCATTTTGA</td>
<td>AGCCCCTACAGACGAGCTCAC</td>
</tr>
<tr>
<td>Bad</td>
<td>AAGTCCGGATCCCCGGAATCC</td>
<td>GCTCACCAGGCTCAAACTCT</td>
</tr>
<tr>
<td>Bcl-2</td>
<td>GTGGGATCAGGGAGATGC</td>
<td>GGCACTGGGCTCTTCA</td>
</tr>
<tr>
<td>p27</td>
<td>TCAACGTCAGAGTGTCTAAGG</td>
<td>CCGGCCCAGGAGATTTCCTG</td>
</tr>
<tr>
<td>c-Fos</td>
<td>CGGGTTCACAGCAGAACTTA</td>
<td>TTGGCACTAGAGCGAGGAGA</td>
</tr>
<tr>
<td>Cyclin D2</td>
<td>GAGTGGAACTTGATGTTTC</td>
<td>CGCAGACGCGATGAAGGT</td>
</tr>
</tbody>
</table>
Statistical analysis and graphing

Statistical analysis (student’s \( t \) test) and graphing were performed using Prism 4 (GraphPad Software, La Jolla, CA). Significance was defined as \( p \leq 0.05 \).
Chapter 3:

Results

The presence of APC-derived molecules on the surface of T cells, as a consequence of trogocytosis, raises the possibility that these molecules play a role in immune modulation. It has previously been shown that trogocytosis may allow T cells to act as antigen presenting cells (146, 147, 156, 158, 190), but the biological effect of trogocytosis on the individual T cell remains unclear. In support of a potentially biologically significant role of trogocytosis on individual cells, our lab previously reported that the acquired MHC:peptide molecules co-localized with elevated phosphorylated tyrosine (pTyr) and the TCR-proximal kinase p56\(^{Lck}\) (Lck) (103). This suggests that the trogocytosed molecules are associated with sustained intracellular signaling after dissociation from APC. In this thesis, I examine the biological effects of trogocytosis on individual CD4\(^+\) T cells, specifically looking at sustained signaling, proliferation, and cell survival.

Measuring Trogocytosis

To identify trog\(^+\) T cells, several different cell-labeling methods were used. Our previous studies relied upon the detection of GFP-tagged MHC:peptide molecules trogocytosed from APC. In addition, we have observed APC plasma membrane transfer onto the T cells by monitoring the trogocytosis of myristoylated-CFP (fig. 7). To compare trogocytosis efficiency of different markers, T cells were incubated with fibroblast APCs and stained using several different staining protocols. Histograms for
several trogocytosed markers are shown in fig. 10. Trogocytosis was measured using GFP-tagged MHC:peptide (fig. 10A) and fluorescently conjugated antibodies (Ab) to I-E<sup>k</sup> (fig. 10B). Murine T cells do not express MHC class II, so the presence of MHC signifies that trogocytosis has occurred. In fig. 10A, GFP mean fluorescence intensity (MFI) is measured on the surface of the T cell using flow cytometry. AD10 T cells recovered from fibroblast APC expressing GFP-tagged MHC (blue line) have a ~30 fold higher MFI than T cells placed in culture without APC (red line). Using Abs specific for trogocytosed MHC (fig. 10B) there is significant transfer of MHC detected (~6 fold higher MFI), but the Ab staining is not as sensitive a measure of trogocytosis compared to the GFP-tagged MHC:peptide (fig. 10A). In fig. 10C, lipophilic dye CM-DiI is used to stain the surface of APC prior to co-culture with T cells. To measure membrane trogocytosis, T cells were recovered from CM-DiI stained fibroblast APCs. The histogram in fig. 10C shows that T cells recovered from CM-DiI stained APC (dotted line) have a 31 fold higher MFI than the unstimulated T cell control (black line). The final method tested was to biotinylate the surface of the APCs prior to incubation with T cells. T cells were stained with streptavidin (SA) conjugated to fluorophore Pacific Blue (PB) to detect biotin trogocytosis. The results in fig. 10D show that biotinylated APC membrane proteins are trogocytosed by the T cells and are easily detected by flow cytometry. Biotin trogocytosis was not as significant as CM-DiI trogocytosis, showing only a 24 fold increase in MFI for the recovered T cells compared to the unstimulated control.

As with the I-E<sup>k</sup> data in figures 10A and 10B, there is significant transfer of biotin from APC to T cells. This verifies that this method is able to efficiently detect
trogocytosis. The data in fig. 10 show that each of these methods can be used to assess trogocytosis.

![Graphs showing different methods of measuring trogocytosis.](image)

**Figure 10. Measuring Trogocytosis using different APC-labeling methods.** Multiple protocols were used to measure trogocytosis from the APC to the CD4$^+$ T cells. (A) The detection of GFP-tagged MHC:peptide trogocytosed from APCs is shown. (B) Similarly, the detection of I-E$k$ trogocytosed from APC shown by anti-I-E$k$ staining is displayed. (A and B) Blue lines represent T cells recovered from APC and red lines represent T cells cultured in the absence of APC. (C) The detection of CM-DiI stained membrane.
trogocytosed from APC. (D) The detection of biotin trogocytosed from APC. To measure biotin trogocytosis, a secondary antibody specific for biotin, streptavidin-Pacific Blue, was used to stain (D). (C and D) Dashed lines represent T cells recovered from APC and the solid filled-in curve represents T cells cultured in the absence of APC. Black number represents recovered T cells and the gray letter represents the T cells minus APC. Data are representative of twelve separate experiments.

**Naïve T cell Trogocytosis**

The experiments shown in fig.10 used T cells that had been primed in vitro with peptide and before use in the in vitro trogocytosis assay. It is unclear how efficient naïve T cells can carry out trogocytosis. To address the question of whether T cells require previous Ag recognition to efficiently perform trogocytosis, naïve CD4+ T cells from an AND x Rag-1−/− mouse were used. The cells were placed in culture with biotinylated fibroblast APC for 6-24 hours (primary stimulation), which has been shown to induce naïve T cell activation (11). The AND x Rag-1−/− mice were used because the T cells were naïve due to the fact that their APCs do not express I-Ek. To determine the extent of naïve T cell trogocytosis, following recovery from APCs the T cells were either stained immediately and analyzed using flow cytometry or were placed in culture and aliquots were taken and stained daily for up to 6 days. After a 6 hour co-culture, naïve T cells were CD69lo, suggesting they were not activated (fig. 11A). In a parallel set of experiments, the naïve T cells recovered from an initial in vitro trogocytosis assay were restimulated 2-3 days following recovery from the primary stimulation. To differentiate between the trogocytosis that occurred during the primary stimulation with the trogocytosis that occurred in the secondary stimulation, T cells were stained for trogocytosed biotin from the primary stimulation using SA-AlexaFluor 488 (AF488) before restimulation, while trogocytosis occurring in the secondary culture was detected using SA-AlexaFluor 647 (AF647). Trogocytosis was compared between the primary
stimulation of 6-24 hrs to the secondary stimulation occurring at 2-3 days following recovery.

Fig. 11 shows that naïve T cells require a second round of stimulation for efficient trogocytosis to occur. Following a six-hour co-culture with fibroblast APC (primary stimulation), the recovered naïve T cells (blue line) showed a 15% increase in biotin on their surface, which is similar to the unstimulated T cells (red line; fig. 11B). In contrast, when cells had been Ag stimulated and then rested for 3 days prior to restimulation, there was a 16 fold increase in trogocytosis (fig.11C). These results show that the initial 6 hr incubation does not result in T cell activation (as measured by CD69 and TCR staining). The level of trogocytosis, while detectable, is minimal (15% increase in MFI). In fig. 11D scatter plots of trogocytosis from the primary stimulation (AF488) versus trogocytosis from the secondary stimulation (AF647), shows the significant difference in trogocytosis that occurred between the two stimulations. 69.1% of the T cells are AF647\text{hi}AF488\text{lo} and only 4.54% of the T cells are AF647\text{hi}AF488\text{hi}, suggesting more trogocytosis occurred after the secondary stimulation. This shows that a majority of the trogocytosis occurred by naïve T cells that did not trogocytose biotin during the primary stimulation.

After resting 3 days, the cells have significantly higher levels of trogocytosis. This data suggest that prior Ag stimulation significantly enhances T cell trogocytosis potential. The increase in trogocytosis could be due to T cells increasing their avidity for APCs.
Figure 11. Primary vs. secondary stimulation of naïve T cell shows increased trogocytosis during the secondary stimulation with APCs. Using the naïve T cell in vitro trogocytosis assay, trogocytosis of surface biotin by naïve AND x Rag-1⁻/⁻ T cells was measured. (A and B) Primary stimulation: gated naïve CD4⁺ T cells recovered after 6-hour co-culture with fibroblast APC stained for CD69 and trogocytosed biotin. (C) Secondary stimulation: following a 3 day rest, T cells were placed with APC and recovered after a second 90 min co-culture. Blue lines represent recovered T cells and the red lines represent T cells placed in culture without APC. (D) Secondary stimulation: gating primary vs. secondary stimulation trogocytosis, using SA-AF488 and SA-AF647. Data are representative of four separate experiments.
**Trogocytosis correlates with naïve T cell proliferation**

The difference in trogocytosis between the primary stimulation and secondary stimulation of naïve CD4\(^+\) T cells can be seen in fig. 11. The limited amount of trogocytosis in the 6 hr primary stimulation of the naïve T cells, seen in fig. 11B may be due to the length of the primary stimulation. To determine whether extended stimulation of naïve T cells could result in enhanced trogocytosis, naïve T cells were Ag stimulated for 24 to 96 hours. This time interval has previously been shown to allow enough time for the naïve T cells to initiate proliferation (11). To induce activation of primary naïve AD10 T cells *in vitro*, MCC\(_{88-103}\) peptide was added to an AD10 whole spleen suspension culture. The physiologic APC in the spleen cell suspension serves as an APC in this experiment. Proliferation of the CD4\(^+\) T cells was monitored by CFSE dilution over four days and daily proliferation vs. trogocytosis results for CD4\(^+\) V\(\beta\)3\(^+\) T cells are shown in fig. 12. Before the cultures were established (day zero) the naïve T cells were bimodal with respect to trogocytosed I-E\(^k\), with approximately 25% of the cells being I-E\(^{k^+}\) directly *ex vivo*. While the frequency number of trog\(^+\) cells varies between the 20 separate experiments, the frequency of MHC\(^+\) TCR transgenic cells directly *ex vivo* ranges between 10 and 25%. This has also been observed in 4 other TCR transgenic and non-transgenic strains our lab has tested (OT-II, 3.L2, AND x B10.BR, B10.BR). The nature of this *in vivo* trogocytosis by naïve cells is unknown, but it is potentially the result of positive selection events (121) or tonic stimulation *in vivo* by selecting ligands in the periphery (191). By day one, the frequency of trog\(^+\) T cells almost doubled to 46.5%. Of note, only the trog\(^+\) population had begun to divide, with 57.8% of the trog\(^+\) cells dividing.
on day one. Thus, the earliest cell division correlates with cells being trog\(^+\), although it is unclear whether this proliferation is driven by trogocytosis.

The results on day two showed that both the trog\(^+\) cells and the trog\(^-\) population were proliferating, but the frequency of dividing cells was still significantly higher for the trog\(^+\) population. By day three, both trog\(^+\) and trog\(^-\) populations were clearly dividing. The trog\(^-\) population was bimodal with 91% of the cells dividing up to 4 times, while 9.0% remained undivided. The proliferation of the trog\(^-\) cells surpassed that of the trog\(^+\) cells by day three; however, the frequency of trog\(^+\) cells had decreased between days two and three. The remaining trog\(^+\) cells had 4.77-fold higher surface I-E\(^k\) than the trog\(^-\). The reduction in the trog\(^+\) cells on day three was likely not due to activation induced cell death, as measured by staining cells with Annexin V and 7-AAD (data not shown). This raises the possibility that an alternative, such as dilution by proliferation by distribution onto daughter cells, was responsible for the decrease in the trog\(^+\) cells. By day four, more than 92% of the CD4\(^+\) cells had divided and few trog\(^+\) cells remain. Of the proliferating cells, more than 82% were trog\(^-\). Taken together, the data in fig. 12 suggest that it is the trog\(^+\) cells that initially divide upon Ag stimulation, followed by the proliferation of trog\(^-\) cells. Additionally, fig. 12 raises the possibility that as the trog\(^-\) cells divide, the trogocytosed I-E\(^k\) may be diluted among daughter cells, reducing the apparent frequency of trog\(^+\) cells and significantly increasing the apparent number of dividing trog\(^-\) cells. Thus, by day four the dividing cells appear to be overwhelmingly trog\(^-\). The data in fig.12 shows that initially naïve T cells do have trogocytosed I-E\(^k\) on their surface (day zero), which differs from the data shown in fig. 11. This difference is likely due to differences in the experimental systems. For fig. 11, naïve T cells are from I-E\(^k\) negative TCR Tg
mice, whereas in fig. 12 T cells are taken from mice that have I-Ek positive APCs, which allow for Ag presentation to occur. From the data in fig. 12, naïve T cells from in vitro priming cultures show a correlation between trogocytosis and proliferation.

Figure 12. In vitro trogocytosis is associated with more rapid proliferation of naïve T cells. (Top) T cells were removed from in vitro priming cultures daily for 4 days and CD4^+Vβ3^+ cells were analyzed for trogocytosed I-Ek and CFSE dilution. CFSE histogram overlay (bottom) comparing T cell proliferation over the course of the 4-day experiment. Data are representative of three separate experiments.

Trogocytosis negative cells recognize antigen and are activated similar to trogocytosis positive cells

After recovery from the in vitro trogocytosis assay, T cells are clearly trog^+ or trog^- . It is unclear whether this reflects differences in activation or the ability to perform
trogocytosis. To examine the hypothesis that in vitro Ag recognition by trog$^-$ cells was not as efficient by the trog$^+$ cells, the standard in vitro trogocytosis assay was used to characterize the activation state of trog$^+$ and trog$^-$ cells. The activation state of trog$^+$ and trog$^-$ T cells was assessed by TCR (V$\beta$3) downmodulation and CD69 upregulation. As predicted, the trog$^+$ T cells had elevated CD69 expression along with substantial TCR downmodulation (fig. 13), indicating that they recognized Ag and were activated. These results are consistent with our previously published data (103). Somewhat unexpectedly, the trog$^-$ T cells also expressed high levels of CD69 and TCR downmodulation, clearly showing that the trog$^-$ T cells also interacted with APCs and were activated. There were small experiment-to-experiment variations in the levels of CD69 and TCR downmodulation, but over the course of 6 separate experiments, these differences were not significant.

The results in fig. 13 suggest that the difference between trog$^+$ and trog$^-$ cells is not simply the lack of Ag recognition by the trog$^-$ cells since it appears that both trog$^+$ and trog$^-$ T cells are similarly activated. To determine if there are biological differences between trog$^+$ and trog$^-$ T cells, CD69 expression was monitored following recovery from APC co-culture for several days.
Figure 13. **Trog**\(^+\) and trog\(^-\) T cells have an activated phenotype.** Both trog\(^+\) and trog\(^-\) AD10 T cells are activated during standard *in vitro* trogocytosis assay using MCC:FKBP APCs. CD69 (left) and TCR (right) expression on T cells recovered from fibroblast APC. Data are representative of six separate experiments. (192)

*Sustained CD69 expression in trog\(^+\) T cells*

In fig. 13, immediately following recovery, both trog\(^+\) and trog\(^-\) T cells have recognized Ag and, based upon CD69 expression, have become activated. Since trogocytosis does not appear to differentiate activated and non-activated T cells, it is unclear whether this phenomenon is physiologically significant. To examine whether there is an advantage to the individual T cell to carry out trogocytosis, changes in CD69 expression overtime in the recovered T cells were examined. After the 90-minute co-culture, recovered T cells were placed in culture dishes at low density to limit potential T-T antigen presentation events. Aliquots were removed from the cultures at different time points up to three days. As shown in fig. 14, there are significant differences in the expression of CD69 between trog\(^+\) and trog\(^-\) CD4\(^+\) T cells. Immediately after removal from APC (time 0), the MFI of CD69 is 4.18 fold higher for trog\(^+\) cells (thick black line) than in the trog\(^-\) T cells (thin black line). The trog\(^-\) cells are nearly identical to unstimulated T cell controls (shaded histogram). In fig. 13 CD69 expression is similar
between trog\(^+\) and trog\(^-\) T cells. The reason for the difference seen at t=0 in fig. 14 could be due to experiment-experiment variations. By 30 min, the CD69 MFI of the trog\(^+\) T cells is 4.9 fold higher than the trog\(^-\) T cells and is similar to the anti-CD3-stimulated positive control (thick gray line). Over the next two hours, CD69 MFI for trog\(^+\) cells remains nearly the same with CD69 levels staying at 3-4 fold higher than trog\(^-\) cells. After 3 hours, the level of CD69 steadily decreases in the trog\(^+\) cells, but remains 5.5 fold higher than trog\(^-\) cells. The level of CD69 in the trog\(^+\) cells remains very similar to the anti-CD3 positive control during this time frame. From twenty-four to seventy-two hours, the trog\(^+\) T cells still have significantly higher CD69 levels, 2-4 fold higher MFI, compared to the trog\(^-\) T cells, which remain similar to the unstimulated control cells. Thus, there is sustained CD69 expression only in trog\(^+\) T cells.

The CD69 results in fig. 14 suggest that there are differences between trog\(^+\) and trog\(^-\) cells following T cell recovery from APC. The higher CD69 levels in trog\(^+\) T cells over time suggests sustained activation in these cells. Since CD69 requires continued signaling for its expression (193), the sustained CD69 on the trog\(^+\) T cells could be due to sustained signaling by the continued engagement of T cell receptors by the trogocytosed molecules. In the remainder of this thesis I will assess whether there are other potential biological advantages for the individual T cells that perform trogocytosis.
Figure 14. Sustained CD69 expression in trog$^+$ CD4$^+$ T cells. (A) AD10 T cells were recovered from the standard *in vitro* trogocytosis assay using MCC:FKBP APCs and fixed immediately (0 h) or were cultured for the indicated times before fixation and Ab staining. The levels of CD69 in CD4$^+$V$\beta$3$^+$ gated trog$^+$ (thick black line), trog$^-$ (thin black line), and unstimulated cells (shaded histogram) are shown for each time point. Cross-linked anti-CD3 (gray line) was used to stimulate TCR signaling as a positive control. (B) Mean fluorescence intensity values for the CD69 flow cytometry data in (A). Data are representative of six separate experiments.
Selective survival of trogocytosis\textsuperscript{+} CD4\textsuperscript{+} T cells in vitro after removal of APC

As shown in figures 13 and 14, both trog\textsuperscript{+} and trog\textsuperscript{-} cells recognize Ag and become activated, but only the trog\textsuperscript{+} cells sustain CD69 expression. To examine whether this difference correlated with any selective advantages for the trog\textsuperscript{+} T cells, I examined the fate of the trog\textsuperscript{+} and trog\textsuperscript{-} cells over several days after removal from GFP-tagged MHC:peptide expressing APCs. T cells recovered from the standard in vitro trogocytosis assay were placed in culture dishes at low density to limit potential T-T Ag presentation events. The frequency of trog\textsuperscript{+} (GFP\textsuperscript{+}) and trog\textsuperscript{-} (GFP\textsuperscript{-}) cells was monitored daily over five days by flow cytometry. On day zero, the trog\textsuperscript{+} T cells made up roughly 35.1\% of the T cells in the cultures, while 64.8\% of the CD4\textsuperscript{+} T cells were trog\textsuperscript{-} (fig. 15). By day one a significant change in the proportion of trog\textsuperscript{+} and trog\textsuperscript{-} T cells in the culture occurred, with the trog\textsuperscript{+} T cells more than doubling to 72.7\% of the CD4\textsuperscript{+} cells. This trend continued on days two and three, where the trog\textsuperscript{+} cells represented 78.8\% and 82.2\% of the viable CD4\textsuperscript{+} cells in culture. By day three the trog\textsuperscript{-} T cell population represented only 17.5\% of the viable CD4\textsuperscript{+} T cells. The population of trog\textsuperscript{+} cells peaked on days three and four at 82.2\% of the viable CD4\textsuperscript{+} cells and decreased slightly on day five to 73.9\%. While there is an overall reduction of viable CD4\textsuperscript{+} cells over the five-day culture period, the proportion of trog\textsuperscript{+} to trog\textsuperscript{-} cells changes dramatically. The results in fig. 15 strongly suggest that trog\textsuperscript{+} cells selectively survive in culture after removal from APCs. There is a slight reduction in the GFP levels between day zero and one, but the level remains fairly constant after day one. This is consistent with our previously published data (103). Interestingly, the trog\textsuperscript{+} cells do not appear to be proliferating significantly in this culture
because the level of GFP on the trog⁺ cells is not significantly reduced on days four and five, as would be expected if the GFP was equally distributed among daughter cells as a result of proliferation. Taken together, the results in figures 12-15 suggest that the trog⁺ cells are activated, proliferate, sustain activation, and selectively survive after removal from APCs.

Figure 15. Selective survival of trog⁺ T cells. AD10 trog⁺ T cells preferentially survive after removal from GFP-tagged MHC:MCC expressing APCs. T cells were recovered from standard in vitro trogocytosis assay and cultured at low density (10⁴/ml). At indicated time points, the presence of trogocytosed GFP-tagged MHC:peptide on CD4⁺Vβ3⁺ gated cells was determined by flow cytometry. The levels of trogocytosed MHC:peptide on day 0 unstimulated (gray shaded) and on recovered T cells at the indicated time point (black line) are shown. Horizontal region markers indicate the frequency of trog⁺ cells in the cultures. Data are representative of four separate experiments. (192)

Sustained TCR-proximal intracellular signaling in trogocytosis⁺ T cells

The results in figures 12-15 suggest that trog⁺ cells have sustained activation and selective survival after removal from APCs compared to trog⁻ cells. It is unclear whether trogocytosed molecules drive this T cell activation and survival or simply mark differentially activated cells that survive. One potential explanation consistent with a
direct role for the trogocytosed molecules in the selective survival of trog+ cells is that these molecules are engaging the TCR and costimulatory receptors on the T cell surface and sustaining intracellular signaling. Consistent with this possibility, we have previously shown that pTyr and the Src kinase Lck accumulate with trogocytosed molecules on T cells after removal of APC (103). To examine the hypothesis that the trogocytosed molecules sustain intracellular signaling leading to T cell activation and survival, TCR signaling in T cells recovered from APC was assessed by flow cytometry and imaging.

As a measure of TCR signaling events, the phosphorylation and activation state of the TCR-proximal Syk family kinase, ZAP-70 and the TCR-distal MAP kinase, ERK were examined. To measure the phosphorylation of molecules in T cells recovered from the standard in vitro trogocytosis assay, phospho-specific Abs and phosflow (185, 194) were used. This technique is as sensitive as traditional biochemical methods (194) and requires significantly fewer cells. To establish the method for analysis of pERK and pZAP-70 levels, AD10 T cells were pharmacologically stimulated. For pERK, T cells were treated with 5 nM phorbol myristate acetate (PMA), which has a structure analogous to diacylglycerol (DAG), to activate PKC and induce the activation of the ERK. To increase intracellular pZAP-70, T cells were treated with 5 µg/ml anti-CD3 in solution, followed by a secondary Ab, to crosslink CD3, leading to ZAP-70 phosphorylation. In fig. 16, T cells show elevated pERK (dotted line) and pZAP-70 (black line) staining following activation with PMA and anti-CD3 compared to the untreated cells (shaded histogram). T cells stimulated with PMA showed a 2.2 fold increase in pERK MFI compared to unstimulated cells, while anti-CD3 stimulated cells showed a 3.1 fold increase in pZAP-70 MFI compared to the unstimulated sample. These
results confirmed that phosflow analysis can be used to measure intracellular signaling in trog$^+$ and trog$^-$ T cells.

**Figure 16. Testing phosflow.** Using the phosflow protocol of Chow et al., pERK and pZAP-70 signaling can be measured following the activation of AD10 T cells. (dotted line) CD4$^+$ T cells were stimulated with 5 nM PMA and then stained with AF647-conjugated pERK antibodies. (solid line) T cells were stimulated with 5 µg/ml anti-CD3 and then stained for AF647-conjugated pZAP-70 antibodies. Data is representative of 3 separate experiments.
After validating this approach, both TCR-proximal and TCR-distal signaling were measured after the recovery of T cells from the in vitro trogocytosis assay. As shown in fig. 17, there are significant differences in the phosphorylation and activation state of ZAP-70 between trog\(^+\) and trog\(^-\) CD4\(^+\) T cells. Immediately after removal from APC (time 0), the MFI of pZAP-70 is 3.03 fold higher for trog\(^+\) T cells (thick black line) than in the trog\(^-\) T cells (thin black line). The trog\(^-\) cells are nearly identical to unstimulated T cell controls (shaded histogram). By 30 min, the pZAP-70 MFI of the trog\(^+\) T cells is 4.2 fold higher than the trog\(^-\) T cells and is nearly identical to the anti-CD3-stimulated positive control (thick gray line). Over the next twenty-four hours, there is a steady decrease in the pZAP-70 MFI for trog\(^+\) cells, but pZAP-70 remains 2.3 fold higher than trog\(^-\) cells. During this time frame, the level of pZAP-70 in the trog\(^+\) cell remains very similar to the anti-CD3 positive control. At seventy-two hours, the trog\(^+\) T cells still have significantly higher pZAP-70 levels (2.8 fold higher MFI) compared to the trog\(^-\) T cells, which remain similar to the unstimulated control cells. Thus, there is sustained TCR-proximal signaling in trog\(^+\) T cells, which were shown to preferentially survive in culture after recovery from APCs (fig. 15).
Figure 17. TCR-proximal signaling is sustained in trogocytosis+ CD4+ T cells using phosflow. (A.) AD10 T cells were recovered from the standard in vitro trogocytosis assay using MCC:FKBP APC and fixed immediately (0 hr) or were cultured for the indicated times before fixation and antibody staining. The level of pZAP-70 in CD4+Vβ3+ gated trog+ (thick black line), trog− (thin black line), and unstimulated cells (shaded histogram) are shown for each time point. Cross-linked anti-CD3 (grey line) was used to stimulate TCR signaling as a positive control. (B.) Mean fluorescence intensity values for the phospho-ZAP-70 flow cytometry data in (A). Data are representative of 6 separate experiments. (192)


**Trogocytosed MHC:peptide molecules co-localize with TCR-proximal signaling molecules in trog^+ T cells**

The flow cytometry data show that TCR-proximal signaling is maintained in the trog^+ cells after removal of APC (fig. 17). To determine whether the elevated pZAP-70 was associated with the trogocytosed molecules on the surface of the T cells, high-resolution microscopy was used to determine the spatial distribution and potential co-localization of TCR-proximal signaling molecules with trogocytosed, GFP-tagged MHC:peptide. To begin, the spatial distribution of the TCR, pZAP-70, total phosphotyrosine (pTyr) and GFP-tagged MHC:peptide molecules were characterized at the immune synapse formed between AD10 T cells and MCC:GFP fibroblast APC. At the T-APC interface, cognate MHC:peptide (green) and the T cell antigen receptor (top-row, blue) are accumulated and colocalized (fig.18), indicating the presence of a mature immune synapse (IS) (184). At the T-APC interface, there is also significant enrichment of pZAP-70 (red) and total phosphotyrosine (blue, bottom). These images are consistent with previous reports characterizing signaling at the IS (97, 102, 154, 184, 195, 196). Interestingly, there is a small spot of trogocytosed MHC:peptide on the distal pole of the T cell (opposite the IS). The presence of trogocytosed MHC:peptide complexes (≥2x background) was observed in 24% of the T-APC conjugates imaged. These trogocytosed molecules accumulated at the distal pole on more than 82% of the trog^+ T cells in T-APC conjugates. Images of T-APC conjugates displaying accumulation of trogocytosed MHC:peptide complexes at the distal pole of the T cell, showed that these molecules colocalized with the TCR (blue) and were associated with elevated pZAP-70 (red) and total pTyr (blue) more than 99% of the time.
Line profiles were used to measure pixel intensity and staining thickness at the synapse and the distal membrane to determine if there was TCR signaling at the trogocytosed molecules (figures 19 and 20). Measuring pixel intensity across the line profile will show where the highest pixel fluorescence occurs for different TCR signaling and trogocytosed molecules staining. Line thickness is used to measure the distance across staining for TCR signaling molecules ≥2x above background fluorescence. In fig. 19, T-APC were imaged for IE\textsuperscript{k} (green) and pLck (red), similar to the conjugates in fig. 18. pLck was used because it is a TCR-proximal signaling molecule and is found near the TCR during its engagement with MHC. Two lines were drawn across the synapse and the distal membrane of the T cells to measure pLck pixel intensity and staining thickness or distances across stains. Fig. 19B line 1 shows a line drawn across the synapse and the distal membrane lacking trogocytosed IE\textsuperscript{k}. Fig. 19B line 2 is drawn across the synapse and the distal membrane containing trogocytosed IE\textsuperscript{k}. When comparing the two lines (fig. 20), the pixel intensity increases at the immune synapse with similar staining thickness for both lines 1 and 2 (bottom fig. 19B). When comparing the distal pole with (line 2) or without (line 1) trogocytosed IE\textsuperscript{k}, line 1 has increased pLck pixel intensity (fig. 20) and a 7.67 fold increase in staining thickness compared to line 2 (bottom fig. 19B). The staining pattern in the images in fig. 18 and 19 are very similar to that of the immunological synapse at the T-APC interface and strongly suggests that these trogocytosed molecules sustain/initiate TCR signaling after transfer onto the T cell.
Figure 18. TCR signaling-associated molecules are associated with trogocytosed molecules on the T cell surface in conjugate with APC. AD10 T cells in conjugate with GFP-tagged MHC:MCC expressing APCs were fixed and stained for the indicated molecules, as described in the Methods section. Elevated pZAP-70 (red) and pTyr (blue, bottom row) levels co-localize with GFP-tagged MHC:peptide (green) and the TCR (blue, top row) at the immune synapse. These molecules also co-localize with trogocytosed MHC:peptide on the distal pole of the T cell. Fluorescence composite image shows position of T cell and APC. For each condition, more than 100 individual T cells were imaged. Images were collected with a 60X objective. Scale bar = 10 µm. (192)
Figure 19. Measuring the thickness of TCR signaling-associated molecules across the distal T cell surface and T-APC interface. Cells were fixed and stained for the indicated molecules, as described in the Methods section. (A) Elevated pLck (red) levels co-localize with GFP-tagged MHC:peptide (green) at the immune synapse. These molecules also co-localize with trogocytosed MHC:peptide on the distal pole of the T cell. Fluorescence composite image shows position of T cell and APC. (B) pLck accumulation at the distal membrane near transferred MHC:peptide is significantly higher than on other regions of the cell. Line profiles were performed, which measure pixel intensity and staining thickness across a line. Lines 1 and 2 measure pLck MFI across the cells. Table shows the thickness of membrane-associated pLck signal $\geq 2x$ background intensity. More than 100 individual T cells were imaged. Lines profiles were created using API SoftWorx software. Images were collected with a 60X objective. Scale bar = 10 $\mu$m.
Figure 20. Measuring pLck staining intensity across the distal T cell surface and the T-APC interface. Graph of the line profiles from fig. 18B measure the pixel intensity of pLck across the T cell distal pole and the T-APC interface. Line 1 measures pLck pixel intensity across the T-APC interface and the distal pole of the T cell with trogocytosed GFP-tagged MHC absent. Line 2 measures pLck pixel intensity across the T-APC interface and the distal pole of the T cell with trogocytosed GFP-tagged MHC. Line profiles were created using API SoftWorx software.
**Sustained TCR-proximal signaling in trog^+ T cells**

The imaging data in figures 18-20 shows that the trogocytosed MHC:peptide appears to co-localize with the TCR and signaling associated molecules and raises the possibility that there is sustained TCR signaling from trogocytosed molecules in T-APC conjugates. To examine the possibility that the trogocytosed molecules sustain TCR signaling in T cells after dissociation from APC, recovered T cells from the standard *in vitro* trogocytosis assay were fixed and stained after an additional 30-minute incubation in the absence of APC. The relationship of the localization of the TCR to signaling molecules, using the TCR-proximal signaling molecules pLck and total pTyr, were examined in 111 T cells. Representative images are shown in fig. 21. Trogocytosis, defined as the presence of GFP-tagged MHC:peptide at least >2x above background fluorescence, was observed in 36% of the T cells imaged. The cell imaged in fig. 21 has two regions of trogocytosed MHC:peptide (indicated by the orange and yellow arrows). These are similar in size and total MHC:peptide accumulation, but the bottom region appears smaller because this image is a single optical section and the bottom spot is axially-centered in a separate focal plane. For both regions, the trogocytosed MHC:peptide localizes with both pLck and pTyr. This staining pattern was observed in 45% of trog^+ cells. These results are similar to our previously published data (103). The localization of TCR-proximal signaling molecules with transferred GFP in fig. 21 suggests that after recovery from APCs the trogocytosed molecules on the T cells sustain TCR-proximal signaling.
**Recovered CD4⁺ T cells**

![Images of recovered CD4⁺ T cells showing staining for various molecules](image)

**Figure 21. Proximal TCR signaling-associated molecules are associated with trogocytosed molecules on the recovered T cell surface.** Recovered AD10 T cells were fixed and stained for the indicated molecules, as described in the Methods section. pLck (red) and total pTyr (blue) co-localize with two trogocytosed MHC:peptide spots (green) (indicated by yellow and orange arrows) on T cells recovered from the *in vitro* trogocytosis assay. Images are from a single focal plane. More than 100 individual T cell were imaged. Images were collected with a 60X objective. Scale bar = 10 µm. (192)

**Sustained TCR-distal signaling in trog⁺ T cells**

To examine whether the trogocytosis-associated TCR-proximal signaling observed in figures 17-21 leads to downstream signaling, the accumulation of phosphorylated ERK1/2 (red) and its spatial distribution relative to the TCR(Vβ3) (blue) and trogocytosed MCC:MHC:GFP (green) were analyzed. As in fig. 21, the cells in fig. 22A have two distinct trogocytosed spots (green) that are ≥2x above background fluorescence. These spots co-localize with accumulated TCR in 96.6% of the 111 trog⁺ T cells imaged. The TCR-distal signaling molecule pERK is also accumulated to the region adjacent to the trogocytosed molecules. While there is little actual pERK co-localization with the TCR or MHC:peptide, this staining pattern is very similar to what has been previously reported for pERK accumulation at the mature immunological synapse (102)
and is consistent with sustained TCR-distal signaling initiated by the trogocytosed molecules.

**Figure 22. Distal TCR signaling-associated molecules are associated with trogocytosed molecules on the recovered T cell surface.** Recovered AD10 T cells were fixed and stained for the indicated molecules, as described in the Methods section. (A) pERK (red) co-associates with trogocytosed MHC:peptide (green) and TCR (blue) on the recovered trog+ cells. pERK and TCR localize with the trogocytosed MHC:peptide molecule (green) region (indicated by the yellow arrow) on T cells recovered from the in vitro trogocytosis assay. Images are from a single focal plane. (B) Mean fluorescent intensity of pERK associated with the trogocytosed MHC:peptide compared to the apical membrane on the same cell. More than 100 individual T cells were imaged. Images were collected with a 60X objective. Scale bar = 10 µm. (192)
To further analyze the potential relationship between trogocytosed molecules and T cell intracellular signaling, the MFI of elevated pERK adjacent to trogocytosed molecules was compared to the amount at a region of the T cell apical membrane devoid of transferred material. The bar graph in fig. 22B shows that the regions adjacent to the trogocytosed molecules have a 56% increase in the level of pERK staining compared to the apical membrane. Taken together, the flow cytometry and imaging data in figures 17-22 suggest that after the trogocytosis event, the transferred MHC:peptide may continue to engage the TCR and sustains intracellular signaling. These results also correlate with the selective survival of T cells, by showing that the trog+ cells could survive longer than trog- cells, due to sustained signaling and activation (fig. 15).

While examining the accumulation of the TCR and pERK with the trogocytosed MHC:peptide complexes, a correlation between the area of the MHC:peptide and the frequency of TCR and pERK co-accumulation was unexpectedly observed. Using three-dimensional image reconstruction, 228 different GFP regions on 47 T cells were analyzed to further assess this potential relationship between the area of the GFP-tagged MHC:peptide (>6x above background) with the TCR and enhanced pERK (≥2x over background). We observed that ~80% of larger GFP regions, defined as being ≥6x6 pixels in size, co-localized with elevated TCR and ~60% had adjacent elevated pERK staining. In comparison, small GFP regions (<6x6 pixels in size) co-localized with TCR only ~20% of the time and only ~22% were adjacent to elevated pERK (fig. 23). These data suggest a correlation between the size of the trogocytosed patches of APC molecules.
on the T cell, and the engagement of the TCR, leading to increased levels of TCR-distal signaling.

Figure 23. Correlation between the size of trogocytosed MHC:peptide and TCR/pERK staining. The relationship of the size of the trogocytosed MHC:peptide region on the T cell with the co-accumulation of TCR (blue) and pERK (red) from images in fig. 22. Small regions were defined as < 6x6 pixels and large ≥ 6x6 pixels. Data based off of more than 100 individual T cells imaged. (192)
**Trogocytosed molecules induce sustained signaling in 
\( ^{+} T \) cells**

The results in figures 17-23 suggest that trogocytosed molecules sustain TCR signaling in T cells after the removal of APCs. However, these results could also be attributed to residual signaling initiated at the immune synapse when T cells initially interacted with APCs. To determine whether the trogocytosed molecules were initiating TCR signaling, the PP2 interruption technique of Faroudi et al (188) was modified. PP2 is a reversible Src family kinase inhibitor that prevents the phosphorylation and activation of Lck during TCR engagement and terminates TCR signaling (188, 189). If the signaling detected by flow cytometry and imaging resulted from residual signaling from the immune synapse, it would be extinguished by PP2 and would not resume after the removal of this inhibitor. However, if the trogocytosed molecules were engaging their receptors on the T cell and sustaining/initiating intracellular signaling, this signaling would be expected to resume upon removal of PP2. To test this hypothesis, T cells were recovered from the standard 90-minute trogocytosis assay and incubated for an additional 30-minutes followed by flow cytometry and imaging analysis of potential TCR-proximal and TCR-distal signaling. Control cultures were treated with 20µM PP2 or were left untreated for the entire 30-minute culture period. In parallel cultures, cells were incubated with 20µM PP2 for 10-minutes at 37°C before the PP2 was washed out. These cells were incubated for an additional 20-minutes in the absence of PP2 before analysis. The results of these experiments are shown in figures 24-28.

In the first set of experiments, TCR-proximal signaling was examined by assessing the level and localization of phosphorylated ZAP-70 in more than a 100 PP2 treated cells by imaging. In addition to representative images seen in fig. 24, quantitative
data analysis of the imaging is shown in the bar graphs in fig. 25. The images in the top row of fig. 24, contained the untreated cells that were incubated in media alone for 30-minutes after removal from APC. There are three distinct GFP-tagged MHC:peptide spots (green) on this particular T cell. These spots co-localized with the TCR Vβ3 (blue) and phosphorylated ZAP-70 (red). In contrast, when cells were cultured in 20µM PP2 for the 30-minute incubation period (bottom row), the MHC:peptide and TCR co-localized normally, but there was minimal pZAP-70 staining and essentially none was associated with either the trogocytosed MHC:peptide or the accumulated TCR. This shows that PP2 treatment extinguishes TCR-proximal signaling, but does not alter TCR-MHC:peptide interactions. Cells treated with PP2 for 10-minutes showed a reduction of total pZAP-70 and no pZAP-70 co-localization with either MHC:peptide or TCR, which was similar to the 30-minute PP2 treatment group (data not shown). The cells treated with PP2 for 10-minutes followed by an additional 20-minute incubation after PP2 removal, displayed a single distinct GFP spot on the cell that was co-localized with both the TCR and elevated pZAP-70.
Figure 24. TCR-proximal signaling is sustained by trogocytosed molecules in trog^+ T cells. Top: T cells were incubated for 30-minutes after recovery from standard trogocytosis assay before fixation and staining. In untreated cells, pZAP-70 (red) and the TCR (blue) co-localize with the trogocytosed MHC:peptide on the T cell surface. Bottom: The TCR and MHC:peptide co-localize on T cells treated with the Src-inhibitor PP2 during the 30-minute incubation period, but there is minimal pZAP-70 detected. Middle: For cells with a 10-minute PP2 treatment to extinguish signaling and before incubation for 20-minutes after PP2 removal, the pZAP-70 level rebounds and it co-localizes with the trogocytosed MHC:peptide and TCR. More than 110 individual T cells were imaged using a 60X objective. Left image for each group is a fluorescence composite image to show the position of the T cell. Scale bar = 10 µm. (192)
Figure 25. pZAP-70 rebounds and localized with trogocytosed GFP-MHC in trog^+ T cells following the removal of PP2. (A) Integrated intensity of pZAP70 ≥6-fold above background from images in fig. 24. 30-minute untreated T cells (green bar), T cells incubated with PP2 for 30-minutes (orange bar) or T cells treated for 10-minutes then incubated for 20-minutes after removal of PP2 (purple bar) are shown. (B) The frequency of pZAP-70 co-localizing with trogocytosed MHC:peptide for each treatment group is shown. (C) The frequency of TCR co-localizing with the TCR. Bars represent mean ± SEM. Horizontal lines indicate statistical comparison between indicated groups; * p ≤ .05. (192)

The bar graph in fig. 25A shows the integrated intensity of pZAP-70 (a measure of fluorescence intensity and accumulation of stains) in areas ≥6x above background on trog^+ cells. After imaging more than 110 trog^+ cells, the 30-minute PP2 treated cells had significantly reduced levels of pZAP-70 staining compared to the 30-minute untreated cells. For the 10-minute PP2 plus 20-minute incubation group, the level of pZAP-70 was restored. Interestingly, the levels were consistently higher for the 10-minute PP2 plus 20-minute incubation group than that found in the untreated cells. The trog^- T cells showed an absence of pZAP-70 staining in all of the treatments (data not shown), consistent with the flow cytometry data in fig. 17. Thus, elevated pZAP-70 seen in the trog^+ 10-minute PP2 treatment plus 20-minute incubation group is not simply due to PP2 treatment and removal, but also requires the presence of trogocytosed molecules.
To confirm that the observed signaling was being initiated at the location of the
trogocytosed molecules, I examined the spatial relationship between elevated pZAP-70
and trogocytosed MHC:peptide molecules on the T cell surface for the different treatment
groups (fig. 25B). For approximately 45% of both the 30-minute untreated cells and the
10-minute PP2 plus 20-minute incubation cells, pZAP-70 co-localized with the
trogocytosed MHC:peptide complexes. In contrast, less than 5% of the cells treated with
PP2 for 30-minutes showed MHC:peptide co-localization with pZAP-70. The significant
reduction in total pZAP-70 and co-localization with the TCR or MHC:peptide for the 30-
minute PP2 treatment group is likely due to the biochemical effects of PP2 on Lck
activation and is not due to inhibition of TCR-MHC:peptide interactions, since these
molecules co-localized equally in the presence or absence of PP2 (fig. 25C). The results
in figures 24-25 strongly support the hypothesis that the trogocytosed molecules continue
to engage their receptors on the T cell surface and sustain TCR-proximal signaling.

After showing that the trogocytosed molecules induced TCR-proximal signaling
upon removal of PP2, TCR-distal signaling was examined using the phosphorylation and
activation of ERK1/2 as a readout. T cells were recovered from the standard trogocytosis
assay and treated with PP2 following the same regimen for the ZAP-70 studies described
above. The extent of ERK phosphorylation in the 3 treatment groups was examined by
phosflow. Similar to the pZAP-70 data, 30-minute PP2 treatment significantly reduced
the amount of phosphorylated ERK in the cell (fig. 26, orange line) compared to the
untreated cells (fig. 26, green line). The pERK1/2 MFI for the 30-minute PP2 treatment
group was 1.6 fold lower than the untreated control. In contrast, the cells treated with PP2
for 10 min followed by an additional 20-minute incubation in the absence of PP2 (fig. 26,
purple line) showed a restoration of pERK1/2 staining. Reminiscent of the pZAP-70 imaging data, the MFI for the 10-minute PP2 plus 20-minute incubation group was 30% higher than the untreated controls and was 1.9 fold higher than the 30-minute PP2 treatment group. It was also 2.4 fold higher than the unstimulated T cell controls. These results are consistent with the TCR-proximal signaling seen in fig. 24 and show that after PP2 inhibition of TCR signaling is removed, TCR-distal signaling is re-initiated within the trog+ T cells.

**Figure 26. TCR-distal signaling is sustained by trogocytosed molecules in trog+ CD4+ T cells using phosflow.** Phosflow data showing the level of pERK1/2 in untreated cells (green line), cells treated with PP2 for 30-minutes (orange line), and cells treated with PP2 followed by a 20-minute incubation after PP2 removal (purple line). Unstimulated cells (shaded histogram) are shown as a control. Data are representative of six separate experiments. (192)
To confirm that the recovery of TCR-distal signaling after PP2 removal is associated with the trogocytosed molecules, imaging experiments were performed. In each row of images in fig. 27, the trogocytosed GFP-MHC:peptide (green), TCR Vβ3 (blue), and pERK1/2 (red) are seen; the right column shows merged images of all three. The untreated group in the top row has several distinct MHC:peptide spots on the recovered T cell. Each of these spots co-localize with the regions of elevated TCR (blue). Adjacent to these TCR-MHC:peptide regions, there is accumulation of elevated pERK. Similar to fig. 22, the pERK does not co-localize with either the MHC:peptide or TCR, but rather is adjacent to these molecules on the T cell. The spatial distribution of the pERK in these trog+ cells is very similar to our previous report regarding pERK accumulation at the immunological synapse (102). When PP2 was present for the entire 30-minute incubation period, the trogocytosed MHC:peptide co-localized with the TCR. Similar to the pZAP-70 data, there was minimal pERK1/2 staining in the 30-minute PP2 group. In the cells incubated for 10-minutes with PP2 followed by an additional 20-minute incubation in the absence of PP2, there were several regions of trogocytosed MHC:peptide complexes that co-localized with the TCR. This is similar to the untreated control (fig. 27, top row). There was also accumulation of pERK1/2 adjacent to the trogocytosed molecules. This complements the flow data (fig. 26) by showing that removal of PP2 allows resumption of TCR-dependent distal signaling from the trogocytosed molecules.
Figure 27. TCR-distal signaling is sustained by trogocytosed molecules in trog+$^{\text{+}}$ CD4+$^{\text{+}}$ T cells. Recovered T cells were incubated for 30-minutes, as described in fig. 24, before staining and imaging. The location of TCR (blue), MHC:peptide (green), and elevated pERK (red) are shown for each treatment group. Data are representative of three separate experiments with more than 100 cells imaged for each treatment group. Images were collected using a 60X objective. Bar = 10µm. (192)

As with the pZAP-70 imaging data, the integrated intensity of pERK (fig. 28A) and the frequency of pERK association with trogocytosed MHC:peptide (fig. 28B) were calculated for more than 100 cells in each treatment group. As expected from the representative images in fig. 27, the cells treated with PP2 for 30-minutes showed an absence of pERK1/2 staining, in contrast to the untreated group. Cells treated for 10-minutes were identical to the 30-minute PP2 treatment (data not shown). The 10-minute
PP2 plus 20-minute incubation group displayed a significant recovery in the integrated intensity for pERK1/2, similar to pZAP-70 results. The pERK integrated intensity for cells treated for 10-minute with PP2 treatment followed by a 20-minute post-PP2 incubation was 10-fold higher than the 30-minute PP2 treatment and 1.6 fold higher than the untreated control. The frequency of elevated pERK adjacent to the trogocytosed MHC:peptide was also quantified for each of the treatment groups (fig. 28B). In 39% of untreated samples and 47% of 10-minute PP2 plus 20 minute post-wash samples, the trogocytosed GFP-tagged MHC:peptide was associated with elevated pERK staining. In contrast, only 8% of the 30-minute PP2 cells showed association of pERK with the trogocytosed molecules.

**Figure 28. pERK1/2 rebounds and localizes with trogocytosed GFP-MHC in trog\(^+\) T cells following the removal of PP2.** (A) Total pERK integrated intensity for areas ≥6-fold above background for each treatment group. (B) The frequency of trogocytosed MHC:peptide molecules that co-associate with elevated pERK (≥2-fold above background) is shown. Bars represent mean ± SEM. Horizontal lines indicate statistical comparison between indicated groups; *p ≤ .05. (192)
Taken together, the results in figures 24-28 show that a 30-minute treatment with PP2 significantly reduces both pERK1/2 and pZAP-70 levels in the trog+ cells. After a 10-minute PP2 treatment, both TCR-proximal (pZAP-70) and TCR-distal (pERK1/2) signaling is re-initiated upon PP2 removal. This re-initiated signaling is dependent upon the trogocytosed molecules. These results strongly suggest that these trogocytosed molecules are engaging their receptors on the T cell surface and are sustaining intracellular signaling after dissociation from the APC. Beyond the TCR:pMHC interactions, the participation of other trogocytosed molecules (i.e., costimulatory and adhesion) is currently unknown.

**T-T Ag presentation**

To examine the cell extrinsic effects of trogocytosis, the potential of trog+ T cells to present Ag was examined. The work of Zhou *et al.* showed that CD4+ T cells could present trogocytosed Ag to naïve T cells, inducing CD25 expression and proliferation of the responder naïve T cells (159). They also showed that when trog+ regulatory T cells were present, immune suppression of the T cells occurred (159). To examine potential T-T Ag presentation following trogocytosis, experiments were set up to analyze the phenotype of the responder naïve T cells. Fig. 29 shows the results of T-T presentation to naïve T cells. Following the T-T presentation assay, trog+ and trog- FACS sorted AD10 T cells were used as APCs. Responder CFSE-labeled naïve AND x B10.BR T cells become activated and also performed trogocytosis when incubated with the trog+ T cells, but not with the trog- cells. In fig. 29A and B, naïve T cells with trog+ T cells (thick black line) had a 1.5 fold increase in CD69 expression and a 2.7 fold increase in CD25 expression compared to naïve T cells with trog- T cells (thin black line). Naïve T cells with trog+ T
cells also showed a 20 fold decrease in the expression of the TCR compared to the naïve T cells with trog⁻ T cells (fig. 29C), showing they had downmodulated their TCR. In contrast, the naïve T cells placed with trog⁻ and unstimulated T cells (shaded histogram) showed similar expression of CD69, CD25, and TCR. Interestingly, naïve T cells with trog⁺ T cells showed a 2.2 fold increase in biotin expression compared to naïve T cells with trog⁻ T cells, suggesting these cells had performed trogocytosis. These results show that T-T presentation may play a role in stimulating naïve T cells during an immune response.
Figure 29. T-T presentation. Trog⁺ and trog⁻ AD10 T cells were sorted and placed with naïve AND x B10.BR T cells at a 1:1 ratio. Naïve cells were CFSE labeled to distinguish from sorted T cells. (A-C) Naïve T cells stimulated with trog⁺ T cells (thick black line) compared to naïve T cells stimulated with trog⁻ T cells (thin black line) and unstimulated naïve T cells (shaded) using CD69, CD25, and TCR staining. (D) Trogocytosed biotin was compared between the three naïve T cell setups. Data are representative of 1 experiment.
Chapter 4:

Discussion

During antigen (Ag) recognition by CD4\(^+\) T cells, three signals are required for the T cells to become activated. The first signal involves the engagement of the T cell receptor (TCR) by cognate MHC:peptide. The TCR binds and recognizes MHC class II and antigenic peptide bound to the MHC. TCR recognition of specific peptide residues and the MHC leads to TCR crosslinking with CD3 and activation of the kinases Lck and ZAP-70. The activation of these molecules leads to a series of signaling cascades that ultimately leads to activation of several transcription factors. The transcription factors activate genes that produce IL-2 and induce activation and proliferation. The second signal involves the engagement of costimulatory molecules, like CD28 on the surface of the T cell. Costimulatory engagement activates kinases leading to a cascade of signaling molecule activation, similar to TCR engagement. In combination with TCR signaling, costimulation leads to increased IL-2 production, activation, and proliferation. The final signal comes from cytokines binding to their specific receptors on the surface of the T cell leading to signaling and gene activation similar to TCR and costimulation engagement.

During Ag recognition by CD4\(^+\) T cells, spatial and temporal rearrangements of the TCR, costimulatory, and adhesion molecules results in the formation of an immunological synapse between the APC and the T cell. The molecules accumulate at the immune synapse and are arranged into distinct supramolecular activation complexes (SMACs) (78). The prototypical T\(_{H1}\) immune synapse is characterized as a bull’s-eye with TCR-MHC:peptide, TCR signaling associated molecules, and CD28/CD80 localized
to the center (the cSMAC). Adhesion molecules, such as ICAM-1/LFA-1, are found in a surrounding peripheral ring (the pSMAC) (78, 79, 86). The overall function of the immunological synapse is unclear; past results have shown that the immune synapse is the site of cytokine secretion (101, 197), cytolytic granule secretion (88), and TCR down-modulation and signaling (154). Our lab has shown that the immune synapse is also the site of APC to CD4+ T cell trogocytosis (103). As T cells dissociate from APCs, MHC:peptide complexes (103, 107), costimulatory molecules (106, 130, 142), plasma membrane lipids (111, 148), and other membrane-bound molecules found on APCs are trogocytosed by the T cells via the immunological synapse (103, 108, 124).

Over the past decade, there have been numerous studies that have examined the mechanism of trogocytosis and the complement of molecules that are transferred, but relatively little is known about the potential biological significance of the capturing of these molecules by the trog+ T cell. The presence of APC-derived molecules on the T cell raises the potential that they could engage receptors on the T cell and sustain intracellular signaling. Sprent’s group has published several papers looking at the ability of APC-derived exosomes to stimulate T cells (198-201), but attachment of exosomes to the surface of the cell is fundamentally different from the integration of these molecules into the plasma membrane via trogocytosis. Using fluorescent microscopy, Wetzel et al. showed that staining for the cytosolic tail of the trogocytosed MHC class II required permeabilization of the T cell membrane (103), suggesting the trogocytosed MHC was integrated into the T cell plasma membrane in its topologically native form. These results are consistent with the results in fig. 9. This finding also correlates with the hypothesis by Martinez-Martin et al. (20) and Dopfer et al. (155), that endosomes containing
trogocytosed APC membrane and membrane molecules fuse with the T cell plasma membrane resulting in the integration of these molecules in the correct orientation. This raises the possibility that sustained signaling via trogocytosis results from trogocytosed molecules engaging their receptors on the T cell surface.

A few studies have looked at the correlation between trogocytosis and sustained T cell signaling, but the correlation remains unclear. In 2005 Zhou et al. showed that CD80+ T cells had sustained NFκB activation and production of selected cytokines (161). However, their results were most likely the result of T-T antigen presentation, not cell autonomous signaling (161). Other reports have looked at the constitutively activated receptor tyrosine kinases (202) and the Ig-like Transcript 2 (ILT2) signaling after trogocytosis (203) in CD8+ T cells, but none have actually addressed sustained signaling in T cells from trogocytosed APC-derived molecules. In this thesis, I have examined the hypothesis that trogocytosed MHC:peptide complexes sustain intracellular signaling within CD4+ T cells after dissociation from APC, leading to sustained T cell activation, proliferation, and survival.

**Kinetics, activation, proliferation, and selective survival of trog+ T cells**

Since murine CD4+ T cells cannot express MHC class II endogenously (175), the presence of these molecules on T cells is due to trogocytosis. I initially examined trogocytosis by testing different cell labeling protocols to determine which was the most efficient at measuring trogocytosis (fig. 10). GFP-tagged MHC class II and the use of anti-I-Ek have been previously shown to be a good measure of trogocytosis (103). These were compared with membrane (CM-Dil) and total protein (surface biotinylation)
trogocytosis to determine which has the best dynamic range when measured by flow cytometry. Both CM-DiI and biotin were more sensitive measures of trogocytosis compared to staining for just MHC. These results are consistent with past results showing significant lipid trogocytosis from APCs onto the T cell (88, 107). The transfer of APC membrane lipids may be the result of membrane fusion between the T-APC, as suggested by Stinchcombe et al. (88). Hudrisier et al. proposed that T cells pull off membrane to use in proliferation and metabolism and, in return, the T cell provides protection for the target cell (108), but there are currently no published data to support this hypothesis.

To further examine trogocytosis, I addressed whether T cells require previous Ag recognition to efficiently perform trogocytosis. Past results have shown that trogocytosis is antigen dose-dependent (105, 107), peptide-specific (105, 107), and requires the immune synapse (103, 108, 124), but very little research has looked at the length of stimulation required for naïve T cell trogocytosis. Using AND x Rag-1⁻ naïve T cells, it was observed that two rounds of stimulation with APCs lead to T cells that are efficient at naïve T cell trogocytosis. During the primary stimulation with APCs for 6-24 hr, little to no trogocytosis occurred (fig. 11B). Following T cell recovery from the primary culture and two additional days in culture, the naïve T cells showed significant trogocytosis after a secondary 90 min stimulation with APC (fig. 11C). Previous studies have reported that naïve T cells have a reduced ability to perform trogocytosis (104, 106, 130, 142, 153), but none has restimulated these cells to examine their trogocytosis capacity upon the secondary challenge. Our results suggest that following the primary stimulation, the T cells increase avidity for the APC, by increased expression of adhesion molecules and integrin activation, allowing for more stable T-APC interactions and, thus, increased
trogocytosis. CD28 expression is also increased in activated T cells and has been linked to increases in transfer (106, 122, 130).

Using in vitro primed naïve T cell cultures, I found that trog T cells do proliferate. Approximately 25% of naïve CD4 T cells from AD10 TCR transgenic mice were MHC class II positive directly ex vivo (fig. 12). Since murine CD4 T cells cannot express MHC class II endogenously (175), the presence of these molecules was due to a trogocytosis event in vivo. The nature of this in vivo trogocytosis by naïve cells is unclear; it could be the result of tonic stimulation by positively selecting ligands in the periphery (191) and/or thymic positive selection events (121). When the AD10 splenic suspensions were stimulated by addition of exogenous MCC antigenic peptide, the frequency of MHC+ (trog+) T cells doubled by day 1 (fig. 12). The trog+ cells were also the first CD4 cells to proliferate. This raises the intriguing possibility that trogocytosis may lower the threshold for activation and proliferation of naïve T cells upon antigen stimulation. The lack of proliferation and activation from the primary stimulation of the naïve T cell could be due to the cells not performing trogocytosis (fig. 11). Several possibilities could explain this observation, including alterations in intracellular signaling and/or increased avidity of the T cells, which could be due to signaling from the trogocytosed molecules.

When trogocytosis by in vitro primed AD10 T was examined, the trog+ T cells were found to have increased TCR-downmodulation and higher levels of CD69 (fig. 13). This suggests that the cells were activated and is consistent with our previously published results (103). It is interesting to note that both trog+ and trog T cells have a similar activation phenotype suggesting that both cell populations recognize Ag and are
activated. It is unclear why the trog⁻ cells did not perform trogocytosis when even anergic T cells efficiently trogocytosed molecules from APC (102). It is not likely due to differences in activation because both populations are similarly activated upon antigen recognition. It is possible that it reflects differences in the avidity of the T cells, their adhesion molecule concentrations, activation states, and/or additional uncharacterized attributes of the two populations of cells.

The significance of trogocytosis becomes clearer once the cells are recovered and placed in culture away from APC. Analyzing sustained expression of CD69 in recovered AD10 T cells over time, the trog⁺ T cells continue to express CD69, while trog⁻ T cells do not. In fig. 14, trog⁺ T cells (thick black line) have high levels of CD69 similar to the anti-CD3 positive control (gray line) for up to one day following recovery. Continual CD69 expression on the surface of the T cell requires TCR:pMHC engagement (19) and TCR signaling (193). I hypothesize that the continued expression of CD69 on the surface the T cells is due to the trogocytosed material engaging receptors on the surface of the T cell after recovery from APC.

This hypothesis is supported by fig. 15, which shows that trog⁺ T cells survive longer in culture following recovery. When cells were recovered from the standard in vitro trogocytosis assay and incubated at low density, a significant change in the frequency of trog⁺ and trog⁻ cells was observed over several days. Immediately after recovery from the APC, the trog⁻ T cells represented almost two-thirds of the CD4⁺ cells. Over the course of several days, the frequency of trog⁺ and trog⁻ cells had reversed so that by day three, the trog⁺ cells made up more than 82% of the viable CD4⁺ T cells and the trog⁻ represented less than 18% of the viable CD4⁺ cells. The level of GFP-tagged MHC
remained fairly constant on the trog$^+$ cells over 5 days, which suggests that the cells weren’t dividing, because proliferation would result in the dilution of trogocytosed molecules onto daughter cells. These results suggest that the trog$^+$ cells were selectively surviving in the cultures, while the trog$^-$ cells were dying.

**Sustained signaling by the trogocytosed material**

One explanation for the preferential survival of the trog$^+$ cells is that the trogocytosed molecules were sustaining intracellular signaling. It would be expected that TCR signaling would cease in recovered cells unless there is continued TCR-MHC:peptide engagement. By flow cytometry it was observed that after the acquisition of cognate MHC:peptide complexes and other APC membrane molecules, there was elevated phosphorylation and activation of both TCR-proximal (pZAP-70) and TCR-distal signaling molecules (pERK1/2) over several days. Using high-resolution light microscopy, it was observed that these TCR-associated signaling molecules accumulated with the TCR and trogocytosed molecules. pERK1/2 was found to co-associate with the trogocytosed material, meaning that pERK1/2 was near the trogocytosed molecules but did not colocalize. This is consistent with Adams et al. and our previous results showing ERK was sequestered and localized near the plasma membrane where the TCR is in activated T cells (102, 204). These data support the hypothesis that the trogocytosed molecules continued to engage their receptors on the T cell and that this “autopresentation” sustained intracellular signaling.

While the detection of phosphorylated and activated signaling molecules in trog$^+$ cells and the co-localization of these molecules with both the TCR and trogocytosed
MHC:peptide supports this model, it does not prove that the trogocytosed molecules are driving the observed signaling. It is possible that the sustained signaling is actually due to residual signaling carried over from the immune synapse between the APC and T cell. To show that this signaling was due to sustained signaling from the trogocytosed molecules, the approach of Faroudi et al. (188) was used. Following the addition of the Src-family of tyrosine kinase inhibitor, PP2, TCR-mediated signaling, both proximal (pZAP-70) and downstream (pERK1/2), ceased. Upon removal of the PP2 and a subsequent 20-minute incubation, both pZAP-70 and pERK1/2 were detected and localized with the TCR and trogocytosed MHC:peptide molecules. This signaling was observed only in the trog^+ cells, not in the trog^- cells. Since the trog^- cells were capable of recognizing antigen and responding (fig. 13), the lack of detectable signaling within these cells leads me to the conclusion that the signaling in the trog^+ cells was cell autonomous and driven by the trogocytosed molecules. If this signaling had been the result of T-T presentation events, there would have been detectable signaling within the trog^- cells, as well, since the trog^- cells make up the majority of the population and are more likely to encounter the trog^+ cells in T-T conjugates. The role of specific trogocytosed molecules (i.e. MHC:peptide, costimulatory molecules, etc.) in the sustained signaling is currently unclear.

These results show that the trogocytosed molecules are responsible for initiating and sustaining signaling by engaging the TCR, suggesting that this leads to the activation and selective survival of trog^+ T cells. The result of trogocytosis could, therefore, play a role in immune modulation. This sustained signaling might lead to clonal exhaustion or activation-induced cell death, helping to turn off an ongoing immune response. Alternatively, this sustained signaling could result in selective survival and to
alterations/increases in T cell effector functions. Further analysis of effector function and cytokine production by trog+ T cells will help clarify the potential role of trogocytosis in immune control.

The imaging experiments shown in fig. 18 demonstrate that in T-APC conjugates a significant accumulation of the TCR and signaling-associated molecules with trogocytosed molecules. Interestingly, the trogocytosed molecules move to a region of the T cell directly opposite the immune synapse more than 82% of the time. This area has been termed the distal pole complex (205, 206). The trogocytosed patches of APC membrane are usually arranged in a circular pattern at the distal pole forming a “trogocytosis crown”. The reason for this segregation of the trogocytosed molecules when conjugated to APC is unclear, but it raises the intriguing possibility that the trogocytosed molecules could play a role in asymmetric T cell division. Asymmetric T cell division involves the segregation of proteins and signaling molecules in a bipolar manner resulting in the differential cell fate (effector versus memory) of daughter cells (207). It is possible that the T cells integrate differential signaling from the immune synapse and from trogocytosed molecules, which may play a role in setting up the observed asymmetric T cell division and differential development of T cell fate.

Sustained signaling after trogocytosis could also resolve an apparent paradox between the duration of Ag stimulation necessary to fully activate CD4+ T cells. Iezzi et al. found that T cell activation required sustained Ag stimulation for up to 6 hours (11). However, intravital microscopy has shown that the duration of initial T-DC interactions are on the order of minutes inside an intact lymph node (208). A pair of previous in vitro studies has shown that T cells form multiple short lived interactions with APC, and that
signals are “summed” to fully activate the T cells (181, 182). These results are consistent with the signaling summation model proposed by Lanzavecchia and colleagues (180). However, Lanzavecchia’s model requires that the summed signaling events temporally overlap. The interval between successive T-APC encounters in both in vivo (208) and in vitro studies is on the order of minutes, during which time signaling would likely be terminated. Partially phosphorylated/activated signaling cascades are refractory to further stimulation leading to inactivation of the cells; a phenomenon underlying the TCR antagonism phenomenon (209, 210). Thus, during the short duration, repeated T-APC interactions observed by others are not strictly in line with the Lanzavecchia model. I propose that trogocytosis could function to sustain intracellular signaling between successive APC interactions allowing for full activation of the T cells via signal summing. The proposed mechanism for how trogocytosis could lead to sustained intracellular signaling is shown in fig. 30.

Figure 30: Autopresentation: proposed hypothesis for how trogocytosis leads to sustained intracellular signaling.
**Trogocytosis signaling and spots**

Imaging done in this thesis and by many others have shown that trogocytosed molecules are usually found in punctate spots on the surface of the T cell (20, 103, 105, 106, 120, 122). In T-APC conjugate images (figures 18-19), trogocytosed GFP:MHC can be seen as one to two spots at the distal pole, as discussed above. It is unclear why trogocytosis leads to punctate spots. The accumulation of trogocytosed molecules into distinct spots suggest that the T cell is concentrating the molecules to accumulate signaling in the area, which is consistent with the sustained signaling imaging data. When the TCR becomes engaged with MHC:peptide, the TCR forms aggregates (35, 36), this could explain why distinct spots form if there is continual engagement of the TCR by trogocytosed MHC:peptide. Wetzel et al. showed in recovered cells that the trogocytosed spots are surrounded by actin cytoskeleton (103), which could help maintain the spots. Fig. 23 is the first data to look at how spot size could correlate to intracellular signaling levels. Spots trogocytosed GFP ≥6x6 pixels showed higher staining for TCR and pERK compared to spots <6x6 pixels. These data suggest that increasing the size of the trogocytosed spot could lead to increased accumulation of intracellular signaling and cytoskeleton keeping the punctate spot together.

**T-T presentation**

The work of Zhou et al. showed that CD4⁺ T cells could present trogocytosed antigen to naïve T cells, showing increases in CD25 and proliferation in the responder naïve T cells (159). They also showed that when trog⁺ regulatory T cells were present,
immune suppression of the T cells occurred (159). To further Zhou et al. work, experiments looking at the phenotype of the responder T cells and the effect of T-T presentation on different responder T cells would help determine a role T-T presentation in an immune response. Using trog$^+$ and trog$^-$ sorted T cells as potential APCs, it was observed that naïve T cells incubated with trog$^+$ and not trog$^-$ T cells became activated. Naïve T cells cultured with trog$^+$ T cells showed increases in CD69, CD25, and downmodulation of the TCR compared to naïve T cell placed in culture with trog$^-$ T cells. Interestingly, naïve T cells trogocytosed biotin from the trog$^+$ T cells, as shown in fig. 29D. Trogocytosis by responder naïve T cells during T-T Ag presentation may play a role in sustained activation and signaling in these cells. Further experiments are needed to determine this and whether an immune synapse forms at the interface. Understanding the role of T-T presentation to naïve T cells (fig. 29) and effector T cells is important in determining the overall role that tropocytosis may play in an immune response.

In conclusion, for the first time, the data presented here demonstrate that trogocytosed molecules continue to engage their receptors on the surface of trog$^+$ T cells to cause sustained intracellular signaling. The selective survival of the trog$^+$ T cells after recovery from the APC co-culture suggests this is most likely due to sustained signaling associated with trogocytosed molecules and provides strong evidence that trogocytosis provides a selective advantage for trog$^+$ T cells.
Chapter 5:

Future Directions:

Peptide affinity

For this thesis, trogocytosis has been monitored during Ag presentation using a strong agonist peptide, MCC, to the TCR. Results by Wetzel et al. have shown that using non-specific peptide-loaded APCs does not lead to T cell trogocytosis (103). What has not been analyzed is the effects on trogocytosis efficiency using varying Ag affinity for the TCR. If trogocytosis occurs with specific Ag recognition, is trogocytosis dependent upon the strength of the TCR-MHC:peptide interaction? Very preliminary peptide affinity experiments have been performed using the fibroblast cell line P13.9H, loaded with an high-affinity agonist peptide (MCC), intermediate-affinity peptide (MCC-A) or a very weak agonist altered peptide ligand (MCC-K99A) (fig. 31A). Using this system we can examine trogocytosis efficiency and can also assess for differences in intracellular signaling and cell survival.

Early lab peptide affinity results are mixed. In several experiments, decreasing TCR affinity decreased trogocytosis efficiency (fig. 31B), except in two experiments where all peptides had similar trogocytosis efficiencies (fig. 31C). In fig. 31B, the bar graph (left) shows a ~32% and ~66% decrease in trogocytosed CD80 MFI compared to the strong agonist (MCC, yellow) to the intermediate agonist (MCC-A, blue) and the weak agonist (MCC-K99A, red), respectively. P-values from bar graphs in fig. 31C (left) showed no significant differences in the average MFI of trogocytosed CD80 (p > 0.05) between the different peptides. Discrepancies in the data may be due to differences in
experimental setups between the fig. 31B and C experiments. In fig. 31B, AD10 T cells were used and in fig. 31C, AND × B10.BR T cells were used. AD10 T cells have shown 10-fold higher affinity for MCC-K99A compared to AND × B10.BR T cells (211). Both AND × B10.BR and AD10 T cells have shown similar affinities for MCC and MCC-A (212, 213). The results in fig. 31 may be due to variations in affinity by the two mouse strain’s TCR for the peptides. Further experiments are necessary to resolve these discrepancies.

<table>
<thead>
<tr>
<th>TCR Affinity of Peptides Used</th>
</tr>
</thead>
<tbody>
<tr>
<td>High: MCC_{85-103} ANERADLIAYLQATK</td>
</tr>
<tr>
<td>Intermediate: MCC AAAAAAAAYAKQATK</td>
</tr>
<tr>
<td>Low: MCC K99A ANERADLIAYLAQATK</td>
</tr>
</tbody>
</table>

A

B

C
Figure 31: Peptide affinity and trogocytosis. Analysis of trogocytosis efficiency by CD4\(^+\) T cells using peptides with differential TCR affinity. Using the standard \textit{in vitro} trogocytosis assay, T cells were co-cultured with the fibroblast cell line P13.9H, loaded with an agonist peptide (MCC) (yellow), intermediate-affinity peptide (MCC-A) (blue) or a very weak agonist altered peptide ligand (MCC-K99A) (red). Peptides shown in A. Trogocytosis was measured using anti-CD80. (B) Using AD10 T cells, bar graphs (left) and histogram overlay (right) showing the MFI and staining of trogocytosed CD80 between T cells cultured with the different peptides. Results in B provided by Sean Wolfe and Timmon Hayes. (C) Using AND T cells, bar graphs (left) show the average MFI over two different experiments for trogocytosed CD80. (right) The histogram overlay shows CD80 staining in one of the two peptide affinity experiments from the bar graph. Bars in B represent mean \(\pm\) SEM. Unstimulated samples (B and C) represent CD4\(^+\) T cells without stimulation from APC. \(P > 0.05\) for bar graphs in C.

\textit{Gene expression of trog}\(^+\) \textit{T cells}

I have shown that sustained signaling occurs in trog\(^+\) T cells, but the biological effects that the sustained signaling has on these T cells is unclear. Using qRT-PCR, gene expression can be analyzed to measure differences between trog\(^+\) and trog\(^-\) T cells. In 2005, Zhou \textit{et al.} showed that autopresentation by APC derived presentasomes led to increases in transcription factors AP-1 and NF\(\kappa\)B (161), but they did not look directly at how trogocytosis affects T cell gene expression. I performed a number of early qRT-PCR experiments looking at FACS-sorted trog\(^-\) and trog\(^+\) T cells following recovery from the standard \textit{in vitro} trogocytosis assay. The data shown in fig. 32 are unclear, showing unexpected decreases in cell cycle promoting molecules, c-Fos and p27, in trog\(^+\) T cells. Similarly, there are increases in both IFN\(\gamma\) and IL-4. These results suggest that there was an APC contamination in our samples that could cause these results. Repeating these experiments will help to pinpoint if there are differences in effector cytokine production in trog\(^+\) and trog\(^-\) cells.
**Figure 32. qRT-PCR of trog⁺ T cells.** FACS purified trog⁺ T cell’s gene expression was compared to unstimulated T cells. qRT-PCR was performed using primers to cell cycle molecules: c-Fos, p27, and Cyclin D2, apoptosis molecules: Bcl-2 and Bad, and cytokines: IFNγ, IL-2, and IL-4. qRT-PCR was performed by the Molecular Biology core at the University of Montana on the BioRad iCycler 5 (Hercules, CA). Fold change numbers were generated using ΔΔCₜ method using Microsoft Excel.

**T cell subsets and trogocytosis**

As suggested from the qRT-PCR data (fig. 32), trogocytosis may be influenced by the effector function of the T cell. Analyzing effector function, specifically within T cell subsets, will help to determine the role of trogocytosis in an immune response. FACS-sorted trog⁺ and trog⁻ T cells, after recovery from APC, can be analyzed using both qRT-PCR and ELISAs.
Promoting the differentiation of T cells into TH1 or TH2 cells can help us determine which subset performs trogocytosis more efficiently. Prior to adding the primed AD10 T cells to the standard *in vitro* trogocytosis assay, we can supplement the primed cultures with cytokines to induce differentiation. By adding IL-4 or IFNγ to the cultures we can induce the cells to become TH2 cells or TH1 cells, respectively. Preliminary results by Lindsay Thuesen suggest that TH2 cells perform trogocytosis more efficiently (data not shown). This experiment, combined with the qRT-PCR and ELISA data, could determine if there is a specific T cell subset that performs trogocytosis more efficiently.

**T-T Ag presentation**

Further studies on T-T presentation could expand on the role of trogocytosis in T cell function. Zhou *et al.* showed that CD4+ T cells could present trogocytosed Ag to naïve T cells, causing increases in CD25 and proliferation of the naïve T cells (159). In contrast, Helft *et al.* showed that T-T presentation led to inhibition of effector/memory T cells (158). Experiments comparing T-T presentation on different responder T cells could help define the potential role of T-T presentation in modulating immune responses.

Understanding the interactions between responder T cells and trog+ T cells should be characterized. Is an immune synapse formed? What is the efficiency? And what is required for T-T Ag presentation? Trog+ and trog- FACS-sorted T cells, following recovery from the standard *in vitro* trogocytosis assay, could be placed in culture with naïve T cells for varying durations of time and ratios of sorted versus naïve cells to determine the length of time and cell dilution needed for efficient Ag presentation. We
could measure the expression of activation markers (like CD69 and CD25) to determine T-T presentation.

Understanding the requirements for T-T Ag presentation, as described above, will help us develop a standard assay for T-T presentation. Once an assay is created, imaging could be done to determine if an immune synapse is formed between the T-APC and the naïve responding cell. Imaging the interface between the two cells for prototypical immune synapse markers (like TCR, MHC, costimulatory molecules (CD80), signaling molecules (PKCθ), and adhesion molecules (ICAM-1)) will allow us to determine if there is segregation of molecules into distinct SMACs, like those found in mature immune synapses.
References


CD3zeta to form a stable central accumulation during negative selection. *Immunity* 16:595-606.


requires activation of T cells but is constitutive in other types of antigen presenting cell. *Cell Immunol* 214:165-172.


159. Zhou, G., Z. C. Ding, J. Fu, and H. I. Levitsky. 2011. Presentation of acquired peptide-MHC class II ligands by CD4+ regulatory T cells or helper cells


interactions of T cells with dendritic cells are dynamic, short lived, and sequential. *Immunity* 13:323-332.


